<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Establishment Labs Holdings Inc. (ESTA) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 12:45 PM EST<br><br>Company Participants<br><br>Filippo Caldini - CEO & Director<br>Rajbir Denhoy - Chief Financial Officer<br><br>Conference Call Participants<br><br>K. Gong - JPMorgan Chase & Co, Research Division<br><br>Presentation<br><br>K. Gong<br>JPMorgan Chase & Co, Research Division<br><br>Okay. Thanks, everyone, for being here. I'm really excited to be introducing some of the management team from Establishment Labs. We're going to be starting off with a presentation from CEO, Peter Caldini, and then Raj Denhoy, CFO, will be joining us for some Q&A afterwards. Filippo Caldini<br>CEO & Director<br><br>Great. Thank you.</td><td>Establishment Labs Holdings Inc. (ESTA) ì œ44íšŒ J.P. Morgan í—¬ìŠ¤ì¼€ì–´ ì»¨í¼ëŸ°ìŠ¤ 2026ë…„ 1ì›” 14ì¼ ì˜¤í›„ 12ì‹œ 45ë¶„ (ë¯¸êµ­ ë™ë¶€ í‘œì¤€ì‹œ)<br><br>íšŒì‚¬ ì°¸ì„ì<br><br>Filippo Caldini - CEO ê²¸ ì´ì‚¬<br>Rajbir Denhoy - ìµœê³ ì¬ë¬´ì±…ì„ì(CFO)<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ì<br><br>K. Gong - JPMorgan Chase & Co, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>ë°œí‘œ<br><br>K. Gong<br>JPMorgan Chase & Co, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>ë„¤, ì°¸ì„í•´ ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. Establishment Labs ê²½ì˜ì§„ ì¼ë¶€ë¥¼ ì†Œê°œí•˜ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ì©ë‹ˆë‹¤. CEOì¸ Peter Caldiniì˜ ë°œí‘œë¡œ ì‹œì‘í•˜ê³ , ì´í›„ CFOì¸ Raj Denhoyê°€ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì— í•¨ê»˜í•  ì˜ˆì •ì…ë‹ˆë‹¤.<br><br>Filippo Caldini<br>CEO ê²¸ ì´ì‚¬<br><br>ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Thank you very much. It's a great pleasure to be here, really an opportunity to share some exciting news and exciting update on Establishment Labs. We just completed a very successful 2025. And I think most importantly, we're very well positioned for strong significant growth in 2026 and beyond. So for those of you that are not as familiar with the Establishment Labs story, we are a medical technology company focused on breast aesthetics and reconstruction. We really drive innovation to improve women's health and well-being. So we've been around for 20 years. We sold over 4.5 million devices worldwide, and we're in 90 countries.</td><td>ê°ì‚¬í•©ë‹ˆë‹¤. ì´ ìë¦¬ì— í•¨ê»˜í•˜ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ì˜ê³ , Establishment Labsì— ëŒ€í•œ í¥ë¯¸ë¡œìš´ ì†Œì‹ê³¼ ìµœì‹  í˜„í™©ì„ ê³µìœ í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ê¸°íšŒì…ë‹ˆë‹¤. ì €í¬ëŠ” ë°©ê¸ˆ ë§¤ìš° ì„±ê³µì ì¸ 2025ë…„ì„ ë§ˆë¬´ë¦¬í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ê°€ì¥ ì¤‘ìš”í•œ ê²ƒì€, 2026ë…„ê³¼ ê·¸ ì´í›„ ê°•ë ¥í•˜ê³  ì˜ë¯¸ ìˆëŠ” ì„±ì¥ì„ ìœ„í•œ ì¢‹ì€ ìœ„ì¹˜ë¥¼ í™•ë³´í–ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. <br><br>Establishment Labsì— ëŒ€í•´ ì˜ ëª¨ë¥´ì‹œëŠ” ë¶„ë“¤ì„ ìœ„í•´ ë§ì”€ë“œë¦¬ë©´, ì €í¬ëŠ” ìœ ë°© ë¯¸ìš© ë° ì¬ê±´ì— ì§‘ì¤‘í•˜ëŠ” ì˜ë£Œê¸°ìˆ  íšŒì‚¬ì…ë‹ˆë‹¤. ì €í¬ëŠ” ì—¬ì„±ì˜ ê±´ê°•ê³¼ ì›°ë¹™ ê°œì„ ì„ ìœ„í•´ í˜ì‹ ì„ ì£¼ë„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” 20ë…„ì˜ ì—­ì‚¬ë¥¼ ê°€ì§€ê³  ìˆìœ¼ë©°, ì „ ì„¸ê³„ì ìœ¼ë¡œ 450ë§Œ ê°œ ì´ìƒì˜ ì˜ë£Œê¸°ê¸°ë¥¼ íŒë§¤í–ˆê³ , 90ê°œêµ­ì— ì§„ì¶œí•´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And just recently, after getting the FDA approval at the end of 2024, we've launched in the U.S., and we've had a very successful start in our first year. Some of that growth is really unprecedented what we've seen in the market in the past. But it's really our science-based innovation that is really setting the standard for breast aesthetics and reconstruction by delivering really differentiated products in the marketplace that's unmatched from a safety and a performance standpoint. We just preannounced our strong results in 2025 on Monday, grew 27% on a global basis.</td><td>ê·¸ë¦¬ê³  ìµœê·¼ 2024ë…„ ë§ FDA ìŠ¹ì¸ì„ ë°›ì€ í›„ ë¯¸êµ­ì—ì„œ ì œí’ˆì„ ì¶œì‹œí–ˆìœ¼ë©°, ì²« í•´ì— ë§¤ìš° ì„±ê³µì ì¸ ì¶œë°œì„ í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ì¥ì˜ ì¼ë¶€ëŠ” ê³¼ê±° ì‹œì¥ì—ì„œ ë³¼ ìˆ˜ ì—†ì—ˆë˜ ì „ë¡€ ì—†ëŠ” ìˆ˜ì¤€ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ëŠ” ì‹¤ì œë¡œ ì•ˆì „ì„±ê³¼ ì„±ëŠ¥ ì¸¡ë©´ì—ì„œ íƒ€ì˜ ì¶”ì¢…ì„ ë¶ˆí—ˆí•˜ëŠ” ì°¨ë³„í™”ëœ ì œí’ˆì„ ì‹œì¥ì— ì œê³µí•¨ìœ¼ë¡œì¨ ìœ ë°© ë¯¸ìš© ë° ì¬ê±´ ë¶„ì•¼ì˜ í‘œì¤€ì„ ì •ë¦½í•˜ê³  ìˆëŠ” ìš°ë¦¬ì˜ ê³¼í•™ ê¸°ë°˜ í˜ì‹  ë•ë¶„ì…ë‹ˆë‹¤. ì›”ìš”ì¼ì— 2025ë…„ ê°•ë ¥í•œ ì‹¤ì ì„ ì‚¬ì „ ë°œí‘œí–ˆìœ¼ë©°, ê¸€ë¡œë²Œ ê¸°ì¤€ìœ¼ë¡œ 27% ì„±ì¥í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>But more importantly, the growth in the U.S., we achieved significant revenue growth, and it's not been seen before in the market in the U.S. And I'm going to provide some more information on that. And then also, we're not stopping there. Real growth moving forward is going to be around our minimally invasive platform. This really has an opportunity to revolutionize the category. It's by providing patients with superior outcomes. And then also what we're seeing in the marketplace.</td><td>í•˜ì§€ë§Œ ë” ì¤‘ìš”í•œ ê²ƒì€ ë¯¸êµ­ì—ì„œì˜ ì„±ì¥ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ìƒë‹¹í•œ ë§¤ì¶œ ì„±ì¥ì„ ë‹¬ì„±í–ˆìœ¼ë©°, ì´ëŠ” ë¯¸êµ­ ì‹œì¥ì—ì„œ ì´ì „ì— ë³¼ ìˆ˜ ì—†ì—ˆë˜ ìˆ˜ì¤€ì…ë‹ˆë‹¤. ì´ì— ëŒ€í•´ì„œëŠ” ì¶”ê°€ ì •ë³´ë¥¼ ì œê³µí•˜ê² ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ì—¬ê¸°ì„œ ë©ˆì¶”ì§€ ì•ŠìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œì˜ ì‹¤ì§ˆì ì¸ ì„±ì¥ì€ ìµœì†Œì¹¨ìŠµ í”Œë«í¼ì„ ì¤‘ì‹¬ìœ¼ë¡œ ì´ë£¨ì–´ì§ˆ ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” í™˜ìë“¤ì—ê²Œ ìš°ìˆ˜í•œ ì¹˜ë£Œ ê²°ê³¼ë¥¼ ì œê³µí•¨ìœ¼ë¡œì¨ í•´ë‹¹ ì¹´í…Œê³ ë¦¬ì— í˜ëª…ì„ ì¼ìœ¼í‚¬ ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë˜í•œ ìš°ë¦¬ê°€ ì‹œì¥ì—ì„œ ëª©ê²©í•˜ê³  ìˆëŠ” ê²ƒë“¤ì´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And some of this is driven by us, but it's also some of the tailwinds you're seeing from GLP-1s that's really giving an opportunity to expand the marketplace, and I'm going to share some information on that as well. But a big focus for us in 2025 is really around driving profitability. And I think we've seen a lot of great success on that. And as we grow and drive our revenue growth, we're very well positioned to drive significant profitability moving forward. Now something about our implants. There is nothing like our implants in the market today.</td><td>ì´ ì¤‘ ì¼ë¶€ëŠ” ìš°ë¦¬ê°€ ì£¼ë„í•˜ê³  ìˆì§€ë§Œ, GLP-1 ì œì œë“¤ë¡œë¶€í„° ë‚˜íƒ€ë‚˜ê³  ìˆëŠ” ìˆœí’ íš¨ê³¼ë„ ìˆì–´ ì‹œì¥ í™•ëŒ€ì˜ ê¸°íšŒë¥¼ ì œê³µí•˜ê³  ìˆìœ¼ë©°, ì´ì— ëŒ€í•œ ì •ë³´ë„ ê³µìœ í•˜ê² ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ 2025ë…„ ìš°ë¦¬ì˜ í° ì´ˆì ì€ ìˆ˜ìµì„± ì œê³ ì— ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ ë¶€ë¶„ì—ì„œ ë§ì€ í›Œë¥­í•œ ì„±ê³¼ë¥¼ ê±°ë‘ì—ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ìš°ë¦¬ê°€ ì„±ì¥í•˜ê³  ë§¤ì¶œ ì„±ì¥ì„ ê²¬ì¸í•¨ì— ë”°ë¼, ì•ìœ¼ë¡œ ìƒë‹¹í•œ ìˆ˜ìµì„±ì„ ì°½ì¶œí•  ìˆ˜ ìˆëŠ” ë§¤ìš° ìœ ë¦¬í•œ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. ì´ì œ ìš°ë¦¬ ì„í”Œë€íŠ¸ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í˜„ì¬ ì‹œì¥ì—ëŠ” ìš°ë¦¬ ì„í”Œë€íŠ¸ì™€ ê°™ì€ ì œí’ˆì´ ì—†ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Every Motiva implant has 4 patented technologies, one of which is SmoothSilk, the SmoothSilk surface that enhances biocompatibility and reduces the level of inflammation as well as bacterial attachment. And when we looked at launching in the U.S. several years ago, we could have come out with a me-too product. It would have been faster, it would have been cheaper, but we really wanted to make sure we came to market and we developed a superior, better product than exists in the marketplace. So by leveraging the technologies, the 4 technologies that we have, we're able to provide implants for patients as well as surgeons that is unmatched from a safety as well as a performance standpoint.</td><td>ëª¨ë“  Motiva ì„í”Œë€íŠ¸ëŠ” 4ê°€ì§€ íŠ¹í—ˆ ê¸°ìˆ ì„ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, ê·¸ ì¤‘ í•˜ë‚˜ê°€ SmoothSilkì…ë‹ˆë‹¤. SmoothSilk í‘œë©´ì€ ìƒì²´ì í•©ì„±ì„ í–¥ìƒì‹œí‚¤ê³  ì—¼ì¦ ìˆ˜ì¤€ê³¼ ì„¸ê·  ë¶€ì°©ì„ ê°ì†Œì‹œí‚µë‹ˆë‹¤. ê·¸ë¦¬ê³  ìˆ˜ë…„ ì „ ë¯¸êµ­ ì‹œì¥ ì§„ì¶œì„ ê²€í† í–ˆì„ ë•Œ, ìš°ë¦¬ëŠ” ëª¨ë°© ì œí’ˆ(me-too product)ì„ ì¶œì‹œí•  ìˆ˜ë„ ìˆì—ˆìŠµë‹ˆë‹¤. ê·¸ê²ƒì´ ë” ë¹ ë¥´ê³  ë¹„ìš©ë„ ì ê²Œ ë“¤ì—ˆì„ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ìš°ë¦¬ëŠ” ì‹œì¥ì— ì§„ì¶œí•˜ì—¬ ê¸°ì¡´ ì‹œì¥ì— ìˆëŠ” ì œí’ˆë³´ë‹¤ ìš°ìˆ˜í•˜ê³  ë” ë‚˜ì€ ì œí’ˆì„ ê°œë°œí•˜ëŠ” ê²ƒì„ í™•ì‹¤íˆ í•˜ê³ ì í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ê°€ ë³´ìœ í•œ 4ê°€ì§€ ê¸°ìˆ ì„ í™œìš©í•¨ìœ¼ë¡œì¨, ìš°ë¦¬ëŠ” í™˜ìì™€ ì™¸ê³¼ì˜ì‚¬ë“¤ì—ê²Œ ì•ˆì „ì„±ê³¼ ì„±ëŠ¥ ì¸¡ë©´ì—ì„œ íƒ€ì˜ ì¶”ì¢…ì„ ë¶ˆí—ˆí•˜ëŠ” ì„í”Œë€íŠ¸ë¥¼ ì œê³µí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Now this is seen with our FDA clinical study data, okay? When you look at the 5-year data point, we have less than 1% device-related complications. Now when you compare that versus some of the competitive products, same time horizon, same type of clinical studies, you'll see up to 10x greater device-related complications. So it's that product of the performance, the safety that has enabled us to have the success that we've had in a market like the U.S. So for example, what we've been able to achieve in the U.S.</td><td>ì´ê²ƒì€ FDA ì„ìƒì‹œí—˜ ë°ì´í„°ì—ì„œ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. 5ë…„ ì‹œì  ë°ì´í„°ë¥¼ ë³´ì‹œë©´, ê¸°ê¸° ê´€ë ¨ í•©ë³‘ì¦ì´ 1% ë¯¸ë§Œì…ë‹ˆë‹¤. ì´ë¥¼ ê²½ìŸ ì œí’ˆë“¤ê³¼ ë¹„êµí•´ë³´ë©´, ë™ì¼í•œ ê¸°ê°„, ë™ì¼í•œ ìœ í˜•ì˜ ì„ìƒì‹œí—˜ì—ì„œ ê¸°ê¸° ê´€ë ¨ í•©ë³‘ì¦ì´ ìµœëŒ€ 10ë°° ë” ë†’ê²Œ ë‚˜íƒ€ë‚©ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŸ¬í•œ ì œí’ˆ ì„±ëŠ¥ê³¼ ì•ˆì „ì„±ì´ ë¯¸êµ­ê³¼ ê°™ì€ ì‹œì¥ì—ì„œ ìš°ë¦¬ê°€ ê±°ë‘” ì„±ê³µì„ ê°€ëŠ¥í•˜ê²Œ í•œ ìš”ì¸ì…ë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´, ë¯¸êµ­ì—ì„œ ìš°ë¦¬ê°€ ë‹¬ì„±í•œ ê²ƒì€...</td></tr>
<tr><td>in terms of our revenue growth and share growth has -- is far superior than what the latest or the last entrant into the category, which is Sientra that's no longer around, that took them 10 years to achieve. As I mentioned, we had a very successful 2025 from a revenue standpoint as well as driving profitability. We preannounced 27% growth. So we're in the revenue range of between $210.5 million and $211.5 million. Very strong fourth quarter. We had a record fourth quarter in our OUS market, but also, most importantly, strong growth in the U.S. market, $45 -- over $45 million in just the first year.</td><td>ë§¤ì¶œ ì„±ì¥ê³¼ ì‹œì¥ ì ìœ ìœ¨ ì„±ì¥ ì¸¡ë©´ì—ì„œ ìš°ë¦¬ì˜ ì„±ê³¼ëŠ” ì¹´í…Œê³ ë¦¬ì— ê°€ì¥ ìµœê·¼ì— ì§„ì…í–ˆë˜ Sientraê°€ 10ë…„ì— ê±¸ì³ ë‹¬ì„±í•œ ê²ƒë³´ë‹¤ í›¨ì”¬ ìš°ìˆ˜í•©ë‹ˆë‹¤. ì°¸ê³ ë¡œ SientraëŠ” í˜„ì¬ ë” ì´ìƒ ì¡´ì¬í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ìš°ë¦¬ëŠ” 2025ë…„ì— ë§¤ì¶œ ì¸¡ë©´ì—ì„œë‚˜ ìˆ˜ìµì„± ê°œì„  ì¸¡ë©´ì—ì„œ ë§¤ìš° ì„±ê³µì ì¸ í•œ í•´ë¥¼ ë³´ëƒˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” 27% ì„±ì¥ì„ ì‚¬ì „ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ì˜ ë§¤ì¶œ ë²”ìœ„ëŠ” 2ì–µ 1,050ë§Œ ë‹¬ëŸ¬ì—ì„œ 2ì–µ 1,150ë§Œ ë‹¬ëŸ¬ ì‚¬ì´ì…ë‹ˆë‹¤. 4ë¶„ê¸° ì‹¤ì ì´ ë§¤ìš° ê°•ë ¥í–ˆìŠµë‹ˆë‹¤. í•´ì™¸ ì‹œì¥ì—ì„œ ê¸°ë¡ì ì¸ 4ë¶„ê¸°ë¥¼ ë‹¬ì„±í–ˆìœ¼ë©°, ê°€ì¥ ì¤‘ìš”í•œ ê²ƒì€ ë¯¸êµ­ ì‹œì¥ì—ì„œì˜ ê°•ë ¥í•œ ì„±ì¥ìœ¼ë¡œ, ì²« í•´ì—ë§Œ 4,500ë§Œ ë‹¬ëŸ¬ ì´ìƒì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So that's from a revenue standpoint, but a lot of our focus was around driving profitability, be more efficient in terms of how we manage the business. We achieved EBITDA positive in Q3. We expect that to be the same in Q4 and continue in that trajectory. But we also improved our cash balance to $75.5 million at the end of last year, end of 2025 versus -- and that's about a $5 million increase from Q3 2025. So let's talk about the U.S. launch, been very successful. It's one of the fastest launches and probably the fastest launch in the breast aesthetics history.</td><td>í•œêµ­ì–´ ë²ˆì—­:<br><br>ë§¤ì¶œ ê´€ì ì—ì„œëŠ” ê·¸ë ‡ì§€ë§Œ, ì €í¬ì˜ ë§ì€ ë…¸ë ¥ì€ ìˆ˜ìµì„± ì œê³ ì™€ ì‚¬ì—… ìš´ì˜ì˜ íš¨ìœ¨ì„± í–¥ìƒì— ì§‘ì¤‘ë˜ì—ˆìŠµë‹ˆë‹¤. 3ë¶„ê¸°ì— EBITDA í‘ìë¥¼ ë‹¬ì„±í–ˆê³ , 4ë¶„ê¸°ì—ë„ ë™ì¼í•œ ìˆ˜ì¤€ì„ ìœ ì§€í•˜ë©° ì´ëŸ¬í•œ ê¶¤ë„ë¥¼ ì´ì–´ê°ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë˜í•œ í˜„ê¸ˆ ì”ì•¡ë„ 2025ë…„ ë§ ê¸°ì¤€ 7,550ë§Œ ë‹¬ëŸ¬ë¡œ ê°œì„ ë˜ì—ˆëŠ”ë°, ì´ëŠ” 2025ë…„ 3ë¶„ê¸° ëŒ€ë¹„ ì•½ 500ë§Œ ë‹¬ëŸ¬ ì¦ê°€í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ë¯¸êµ­ ì‹œì¥ ì¶œì‹œì— ëŒ€í•´ ë§ì”€ë“œë¦¬ìë©´, ë§¤ìš° ì„±ê³µì ì´ì—ˆìŠµë‹ˆë‹¤. ìœ ë°© ë¯¸ìš© ë¶„ì•¼ ì—­ì‚¬ìƒ ê°€ì¥ ë¹ ë¥¸ ì¶œì‹œ ì¤‘ í•˜ë‚˜ì´ë©°, ì•„ë§ˆë„ ê°€ì¥ ë¹ ë¥¸ ì¶œì‹œì¼ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>And one of the key drivers for that success is really we've been able to assemble a best-in-class organization over the last 18 months. And you couple the organization with the implants and the profile in terms of our performance and safety has enabled us to achieve the $45 million in just the first year. We estimate that we're exiting -- or we exited 2025 at a market share rate of approximately 20%. And we keep on driving that growth with adding additional accounts, increasing the utilization rate. So that's just the beginning. So that's our first year, and we expect continued growth in 2026 and beyond. What's some of the drivers for the market share growth in the U.S.</td><td>ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ì„±ê³µì˜ í•µì‹¬ ë™ë ¥ ì¤‘ í•˜ë‚˜ëŠ” ì§€ë‚œ 18ê°œì›” ë™ì•ˆ ìµœê³  ìˆ˜ì¤€ì˜ ì¡°ì§ì„ êµ¬ì¶•í•  ìˆ˜ ìˆì—ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ì¡°ì§ê³¼ ì„í”Œë€íŠ¸ë¥¼ ê²°í•©í•˜ê³ , ì„±ëŠ¥ ë° ì•ˆì „ì„± ì¸¡ë©´ì—ì„œì˜ ìš°ìˆ˜í•œ ì‹¤ì  í”„ë¡œíŒŒì¼ì„ í†µí•´ ì²« í•´ì—ë§Œ 4,500ë§Œ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” 2025ë…„ì„ ì•½ 20%ì˜ ì‹œì¥ì ìœ ìœ¨ë¡œ ë§ˆê°í–ˆê±°ë‚˜ ë§ˆê°í•  ê²ƒìœ¼ë¡œ ì¶”ì •í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¶”ê°€ ê±°ë˜ì²˜ í™•ë³´ì™€ í™œìš©ë¥  ì¦ê°€ë¥¼ í†µí•´ ì§€ì†ì ìœ¼ë¡œ ì„±ì¥ì„ ê²¬ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì€ ì‹œì‘ì— ë¶ˆê³¼í•©ë‹ˆë‹¤. ì´ê²ƒì´ ìš°ë¦¬ì˜ ì²« í•´ì˜€ìœ¼ë©°, 2026ë…„ê³¼ ê·¸ ì´í›„ì—ë„ ì§€ì†ì ì¸ ì„±ì¥ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ì‹œì¥ì—ì„œ ì‹œì¥ì ìœ ìœ¨ ì„±ì¥ì˜ ì£¼ìš” ë™ë ¥ì€ ë¬´ì—‡ì¸ê°€ìš”?</td></tr>
<tr><td>If you think about the breast implant category, there really hasn't been a lot of new news. It's been relatively stagnant. There hasn't been a lot of innovation. There's been limited marketing support, and we came in with new news, new innovation, but also a lot of marketing support. And we've been able to not only drive awareness for Motiva, but also for the category as a whole. For some examples of that, we had over 9.2 billion impressions in the first year. And I think it's what's very monumental and very unique in the category is patients are walking in, talking to the surgeon and asking for Motiva by name. That's unheard of in the industry.</td><td>ìœ ë°© ë³´í˜•ë¬¼ ì¹´í…Œê³ ë¦¬ë¥¼ ìƒê°í•´ë³´ë©´, ì‹¤ì œë¡œ ìƒˆë¡œìš´ ì†Œì‹ì´ ë§ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ìƒëŒ€ì ìœ¼ë¡œ ì •ì²´ë˜ì–´ ìˆì—ˆì£ . í˜ì‹ ì´ ë§ì§€ ì•Šì•˜ê³ , ë§ˆì¼€íŒ… ì§€ì›ë„ ì œí•œì ì´ì—ˆìŠµë‹ˆë‹¤. ê·¸ëŸ°ë° ì €í¬ëŠ” ìƒˆë¡œìš´ ì†Œì‹, ìƒˆë¡œìš´ í˜ì‹ ê³¼ í•¨ê»˜ ë§ì€ ë§ˆì¼€íŒ… ì§€ì›ì„ ê°€ì§€ê³  ì‹œì¥ì— ì§„ì…í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ëŠ” Motivaì— ëŒ€í•œ ì¸ì§€ë„ë¿ë§Œ ì•„ë‹ˆë¼ ì¹´í…Œê³ ë¦¬ ì „ì²´ì— ëŒ€í•œ ì¸ì§€ë„ë„ ë†’ì¼ ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ëª‡ ê°€ì§€ ì˜ˆë¥¼ ë“¤ë©´, ì²« í•´ì— 92ì–µ ê±´ ì´ìƒì˜ ë…¸ì¶œ(impressions)ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì œ ìƒê°ì— ì´ ì¹´í…Œê³ ë¦¬ì—ì„œ ë§¤ìš° ê¸°ë…ë¹„ì ì´ê³  ë§¤ìš° ë…íŠ¹í•œ ì ì€ í™˜ìë“¤ì´ ì§ì ‘ ì°¾ì•„ì™€ì„œ ì™¸ê³¼ì˜ì‚¬ì™€ ëŒ€í™”í•˜ë©° Motivaë¥¼ ì´ë¦„ìœ¼ë¡œ ì§€ì •í•´ì„œ ìš”ì²­í•œë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒì€ ì—…ê³„ì—ì„œ ì „ë¡€ê°€ ì—†ëŠ” ì¼ì…ë‹ˆë‹¤.</td></tr>
<tr><td>One of the key drivers was in terms of creating that awareness, and we're the first ones to actually use celebrity endorsers, and we did a deal, a sponsorship with Meghan Trainor, which was highly successful. It not only helped drive awareness for Motiva, but it was also really starting to increase the awareness or the era of transparency. So women are starting to talk more openly about getting breast augmentation and really starting to remove the stigma attached to it. Motiva breast implants was the fastest-growing procedure in real self in 2025, so really a monumental growth. So marketing was a key driver for us in 2025, and that will continue in 2026 and beyond.</td><td>ì£¼ìš” ë™ì¸ ì¤‘ í•˜ë‚˜ëŠ” ì¸ì§€ë„ ì œê³ ì˜€ìœ¼ë©°, ì €í¬ëŠ” ìœ ëª…ì¸ í™ë³´ëŒ€ì‚¬ë¥¼ í™œìš©í•œ ìµœì´ˆì˜ ê¸°ì—…ì…ë‹ˆë‹¤. ë©”ê±´ íŠ¸ë ˆì´ë„ˆ(Meghan Trainor)ì™€ ìŠ¤í°ì„œì‹­ ê³„ì•½ì„ ì²´ê²°í–ˆê³ , ì´ëŠ” ë§¤ìš° ì„±ê³µì ì´ì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” ëª¨í‹°ë°”(Motiva)ì— ëŒ€í•œ ì¸ì§€ë„ë¥¼ ë†’ì´ëŠ” ë° ë„ì›€ì´ ë˜ì—ˆì„ ë¿ë§Œ ì•„ë‹ˆë¼, íˆ¬ëª…ì„±ì˜ ì‹œëŒ€ë¥¼ ì—¬ëŠ” ë°ë„ ê¸°ì—¬í•˜ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ì—¬ì„±ë“¤ì´ ìœ ë°©í™•ëŒ€ìˆ ì— ëŒ€í•´ ë”ìš± ê³µê°œì ìœ¼ë¡œ ì´ì•¼ê¸°í•˜ê¸° ì‹œì‘í–ˆê³ , ì´ì— ëŒ€í•œ ë‚™ì¸ì„ ì‹¤ì§ˆì ìœ¼ë¡œ ì œê±°í•˜ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ëª¨í‹°ë°” ìœ ë°© ë³´í˜•ë¬¼ì€ 2025ë…„ ë¦¬ì–¼ì…€í”„(RealSelf)ì—ì„œ ê°€ì¥ ë¹ ë¥´ê²Œ ì„±ì¥í•œ ì‹œìˆ ì´ì—ˆìœ¼ë©°, ì •ë§ ê¸°ë…ë¹„ì ì¸ ì„±ì¥ì´ì—ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë§ˆì¼€íŒ…ì€ 2025ë…„ ì €í¬ì˜ í•µì‹¬ ë™ë ¥ì´ì—ˆìœ¼ë©°, ì´ëŠ” 2026ë…„ê³¼ ê·¸ ì´í›„ì—ë„ ê³„ì†ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>What are some of the other drivers for market share growth in the U.S. in 2026? We've talked about launching PreservÃ©. It's our minimally invasive platform. We've rolled it out in OUS with a lot of success. We've had a number of early surgeons working with that product back in August. So it's about 50 early experienced surgeons and very positive success. And we see that the minimally invasive platform has a lot of potential, not only for us to steal share but expand the category as well. We also submitted a PMA supplement for our smaller sizes. And we believe that there's about 10% of the market that we're not currently serving that we don't have our complete matrix.</td><td>2026ë…„ ë¯¸êµ­ ì‹œì¥ ì ìœ ìœ¨ ì„±ì¥ì„ ê²¬ì¸í•  ë‹¤ë¥¸ ìš”ì¸ë“¤ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ? ì €í¬ëŠ” PreservÃ© ì¶œì‹œì— ëŒ€í•´ ë…¼ì˜í–ˆìŠµë‹ˆë‹¤. ì´ê²ƒì€ ì €í¬ì˜ ìµœì†Œ ì¹¨ìŠµ í”Œë«í¼ì…ë‹ˆë‹¤. í•´ì™¸ ì‹œì¥(OUS)ì—ì„œ í° ì„±ê³µì„ ê±°ë‘ë©° ì¶œì‹œí–ˆê³ , ì§€ë‚œ 8ì›”ë¶€í„° ë‹¤ìˆ˜ì˜ ì´ˆê¸° ë„ì… ì˜ì‚¬ë“¤ì´ ì´ ì œí’ˆì„ ì‚¬ìš©í•´ì™”ìŠµë‹ˆë‹¤. ì•½ 50ëª…ì˜ ì´ˆê¸° ê²½í—˜ ì˜ì‚¬ë“¤ì´ ë§¤ìš° ê¸ì •ì ì¸ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì´ ìµœì†Œ ì¹¨ìŠµ í”Œë«í¼ì´ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ë³´í•  ë¿ë§Œ ì•„ë‹ˆë¼ ì¹´í…Œê³ ë¦¬ ìì²´ë¥¼ í™•ëŒ€í•  ìˆ˜ ìˆëŠ” í° ì ì¬ë ¥ì„ ê°€ì§€ê³  ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ë˜í•œ ì €í¬ëŠ” ì†Œí˜• ì‚¬ì´ì¦ˆì— ëŒ€í•œ PMA ë³´ì™„ ì‹ ì²­ì„œë¥¼ ì œì¶œí–ˆìŠµë‹ˆë‹¤. í˜„ì¬ ì €í¬ê°€ ì™„ì „í•œ ì œí’ˆ ë¼ì¸ì—…ì„ ê°–ì¶”ì§€ ëª»í•´ ì„œë¹„ìŠ¤í•˜ì§€ ëª»í•˜ê³  ìˆëŠ” ì‹œì¥ì´ ì•½ 10% ì •ë„ ìˆë‹¤ê³  íŒë‹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So by getting that approval, we'll be able to close that gap and continue to generate additional sales. A key milestone for us is when we'll get the recon indication. We submitted the PMA supplement at the end of last year, and it's really the time line dependent on FDA. But this is a sizable opportunity for us in the U.S. We believe once we get recon indication, we're going to generate the same type of share that we're getting in the augmentation space. Another key driver for us in the U.S., and we've talked about this previously, is continuing to expand our sales force. We're going to be adding up to 15 reps in 2026, and that continues to be around the augmentation space.</td><td>ìŠ¹ì¸ì„ ë°›ê²Œ ë˜ë©´ ê·¸ ê²©ì°¨ë¥¼ í•´ì†Œí•˜ê³  ì¶”ê°€ ë§¤ì¶œì„ ì§€ì†ì ìœ¼ë¡œ ì°½ì¶œí•  ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ì €í¬ì—ê²Œ ì¤‘ìš”í•œ ì´ì •í‘œëŠ” ì¬ê±´(reconstruction) ì ì‘ì¦ì„ ì–¸ì œ ë°›ëŠëƒì…ë‹ˆë‹¤. ì‘ë…„ ë§ì— PMA ë³´ì™„ìë£Œë¥¼ ì œì¶œí–ˆìœ¼ë©°, ì‹¤ì œë¡œ ì¼ì •ì€ FDAì— ë‹¬ë ¤ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ëŠ” ë¯¸êµ­ì—ì„œ ì €í¬ì—ê²Œ ìƒë‹¹í•œ ê¸°íšŒì…ë‹ˆë‹¤. ì¬ê±´ ì ì‘ì¦ì„ ë°›ê²Œ ë˜ë©´, í™•ëŒ€(augmentation) ë¶„ì•¼ì—ì„œ ì–»ê³  ìˆëŠ” ê²ƒê³¼ ë™ì¼í•œ ìˆ˜ì¤€ì˜ ì‹œì¥ì ìœ ìœ¨ì„ ì°½ì¶œí•  ê²ƒìœ¼ë¡œ ë¯¿ìŠµë‹ˆë‹¤. ë¯¸êµ­ì—ì„œ ì €í¬ì˜ ë˜ ë‹¤ë¥¸ í•µì‹¬ ì„±ì¥ ë™ë ¥ì€, ì´ì „ì—ë„ ë§ì”€ë“œë ¸ë“¯ì´, ì˜ì—… ì¸ë ¥ì„ ì§€ì†ì ìœ¼ë¡œ í™•ëŒ€í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. 2026ë…„ì— ìµœëŒ€ 15ëª…ì˜ ì˜ì—…ì‚¬ì›ì„ ì¶”ê°€í•  ì˜ˆì •ì´ë©°, ì´ëŠ” í™•ëŒ€ ë¶„ì•¼ë¥¼ ì¤‘ì‹¬ìœ¼ë¡œ ì´ë£¨ì–´ì§ˆ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Obviously, once we get the recon indication, there will be another step change in terms of supporting that side of the business. And we keep on growing accounts. We're over 1,500 right now, but it's also not only growing the accounts, it's increasing the utilization rate as the adoption curve continues to move forward. Now a little bit about the recon indication. This is a tremendous opportunity for us. I mentioned that we submitted the PMA supplement at the end of last year. The size of the recon business in the U.S. is the same size of the augmentation from a revenue standpoint. So it really gives us an opportunity to double the market that we're currently competing in.</td><td>ë¬¼ë¡  ì¬ê±´ìˆ (recon) ì ì‘ì¦ì„ íšë“í•˜ê²Œ ë˜ë©´, í•´ë‹¹ ì‚¬ì—… ë¶€ë¬¸ì„ ì§€ì›í•˜ëŠ” ì¸¡ë©´ì—ì„œ ë˜ ë‹¤ë¥¸ ë‹¨ê³„ì  ë³€í™”ê°€ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ê³„ì†í•´ì„œ ê±°ë˜ì²˜ë¥¼ ëŠ˜ë ¤ê°€ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ 1,500ê°œê°€ ë„˜ëŠ”ë°, ë‹¨ìˆœíˆ ê±°ë˜ì²˜ë¥¼ ëŠ˜ë¦¬ëŠ” ê²ƒë¿ë§Œ ì•„ë‹ˆë¼ ë„ì… ê³¡ì„ ì´ ê³„ì† ì§„ì „ë¨ì— ë”°ë¼ í™œìš©ë¥ ì„ ë†’ì´ëŠ” ê²ƒë„ ì¤‘ìš”í•©ë‹ˆë‹¤. ì´ì œ ì¬ê±´ìˆ  ì ì‘ì¦ì— ëŒ€í•´ ì¡°ê¸ˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ê²ƒì€ ìš°ë¦¬ì—ê²Œ ì—„ì²­ë‚œ ê¸°íšŒì…ë‹ˆë‹¤. ì œê°€ ë§ì”€ë“œë ¸ë“¯ì´ ì‘ë…„ ë§ì— PMA ë³´ì™„ìë£Œë¥¼ ì œì¶œí–ˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ë‚´ ì¬ê±´ìˆ  ì‹œì¥ì˜ ê·œëª¨ëŠ” ë§¤ì¶œ ê´€ì ì—ì„œ í™•ëŒ€ìˆ (augmentation) ì‹œì¥ê³¼ ë™ì¼í•œ ê·œëª¨ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŠ” ìš°ë¦¬ê°€ í˜„ì¬ ê²½ìŸí•˜ê³  ìˆëŠ” ì‹œì¥ì„ ë‘ ë°°ë¡œ í™•ëŒ€í•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ì œê³µí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Now we are already in over 200 locations with our Flora Tissue Expander. So once we get the indication approval, we already have a head start in terms of driving growth for the indication -- the recon indication. And so we expect the acceleration to be very quick. Now a key driver for us moving forward in the U.S. with the minimally invasive as well as OUS is around the minimally invasive platform. PreservÃ© will be launching in the U.S. Outside the U.S., we launched PreservÃ©. We also have Mia. And this is really an opportunity, as I mentioned before, to not only drive growth for us, but it's an opportunity to drive share and expand the category.</td><td>í˜„ì¬ ì €í¬ëŠ” ì´ë¯¸ Flora ì¡°ì§ í™•ì¥ê¸°(Tissue Expander)ë¥¼ 200ê°œ ì´ìƒì˜ ì˜ë£Œê¸°ê´€ì— ê³µê¸‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì ì‘ì¦ ìŠ¹ì¸ì„ ë°›ê²Œ ë˜ë©´, ì¬ê±´(reconstruction) ì ì‘ì¦ì˜ ì„±ì¥ì„ ê²¬ì¸í•˜ëŠ” ë° ìˆì–´ ì´ë¯¸ ì„ ë‘ ì¶œë°œì„ í•˜ê³  ìˆëŠ” ì…ˆì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì €í¬ëŠ” ì„±ì¥ ê°€ì†í™”ê°€ ë§¤ìš° ë¹ ë¥´ê²Œ ì´ë£¨ì–´ì§ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ì•ìœ¼ë¡œ ë¯¸êµ­ ë‚´ ìµœì†Œì¹¨ìŠµ ë¶€ë¬¸ê³¼ í•´ì™¸ ì‹œì¥ì—ì„œ ì €í¬ì˜ í•µì‹¬ ì„±ì¥ ë™ë ¥ì€ ìµœì†Œì¹¨ìŠµ í”Œë«í¼ì„ ì¤‘ì‹¬ìœ¼ë¡œ ì „ê°œë  ê²ƒì…ë‹ˆë‹¤. PreservÃ©ëŠ” ë¯¸êµ­ì—ì„œ ì¶œì‹œë  ì˜ˆì •ì…ë‹ˆë‹¤. ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œëŠ” PreservÃ©ë¥¼ ì¶œì‹œí–ˆìœ¼ë©°, Mia ì œí’ˆë„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ì´ëŠ” ì €í¬ì—ê²Œ ë‹¨ìˆœíˆ ì„±ì¥ì„ ê²¬ì¸í•  ê¸°íšŒì¼ ë¿ë§Œ ì•„ë‹ˆë¼, ì‹œì¥ì ìœ ìœ¨ì„ í™•ëŒ€í•˜ê³  ì¹´í…Œê³ ë¦¬ ìì²´ë¥¼ í™•ì¥í•  ìˆ˜ ìˆëŠ” ê¸°íšŒì…ë‹ˆë‹¤.</td></tr>
<tr><td>So this unique approach using Motiva implants and tools has the opportunity to provide superior outcome for patients. And really doing that by focusing on really reducing and maintaining as much as the breast tissue as well as the breast functionality. So those results, you don't need general anesthesia. The recovery time is incredibly fast versus traditional augmentation, which is far more invasive and it's under 15 minutes. And the incision, which leads to a smaller scar, is certainly much more smaller. So we see this as a significant driver for our business. In 2026, it should represent over $30 million in revenue.</td><td>ë”°ë¼ì„œ Motiva ì„í”Œë€íŠ¸ì™€ ë„êµ¬ë¥¼ ì‚¬ìš©í•˜ëŠ” ì´ ë…íŠ¹í•œ ì ‘ê·¼ë²•ì€ í™˜ìë“¤ì—ê²Œ ìš°ìˆ˜í•œ ê²°ê³¼ë¥¼ ì œê³µí•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‹¤ì œë¡œ ìœ ë°© ì¡°ì§ê³¼ ìœ ë°© ê¸°ëŠ¥ì„ ìµœëŒ€í•œ ìœ ì§€í•˜ê³  ë³´ì¡´í•˜ëŠ” ë° ì¤‘ì ì„ ë‘ì–´ ì´ë¥¼ ì‹¤í˜„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê²°ê³¼ë¡œ, ì „ì‹  ë§ˆì·¨ê°€ í•„ìš”í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. íšŒë³µ ì‹œê°„ì€ í›¨ì”¬ ë” ì¹¨ìŠµì ì´ê³  15ë¶„ ì´ìƒ ì†Œìš”ë˜ëŠ” ê¸°ì¡´ì˜ í™•ëŒ€ìˆ ì— ë¹„í•´ ë§¤ìš° ë¹ ë¦…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë” ì‘ì€ í‰í„°ë¡œ ì´ì–´ì§€ëŠ” ì ˆê°œ ë¶€ìœ„ë„ í™•ì‹¤íˆ í›¨ì”¬ ë” ì‘ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ì´ê²ƒì„ ìš°ë¦¬ ì‚¬ì—…ì˜ ì¤‘ìš”í•œ ì„±ì¥ ë™ë ¥ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. 2026ë…„ì—ëŠ” 3ì²œë§Œ ë‹¬ëŸ¬ ì´ìƒì˜ ë§¤ì¶œì„ ë‚˜íƒ€ë‚¼ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>Now a little bit about the minimally invasive, why we see this as a market expansion opportunity. We've done some market research, but we're also hearing from the early experienced surgeons in the U.S. It really targets a segment of women that is currently untapped in the category. These tend to be women that are more affluent, but there are also a lot of barriers in terms of general anesthesia, the recovery time. So this really targets those type of consumers. In some of the market research, we've seen that 1 out of 4 patients that are exposed to PreservÃ© are willing or interested in doing a breast augmentation and 83% of those women want to do a PreservÃ© procedure.</td><td>ìµœì†Œì¹¨ìŠµ ì‹œìˆ ì— ëŒ€í•´ ì¡°ê¸ˆ ë§ì”€ë“œë¦¬ìë©´, ì €í¬ê°€ ì´ê²ƒì„ ì‹œì¥ í™•ëŒ€ ê¸°íšŒë¡œ ë³´ëŠ” ì´ìœ ì…ë‹ˆë‹¤. ì €í¬ëŠ” ì‹œì¥ ì¡°ì‚¬ë¥¼ ì§„í–‰í–ˆê³ , ë¯¸êµ­ ë‚´ ì´ˆê¸° ê²½í—˜ì´ ìˆëŠ” ì™¸ê³¼ì˜ë“¤ë¡œë¶€í„°ë„ ì˜ê²¬ì„ ë“£ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” í˜„ì¬ ì´ ì¹´í…Œê³ ë¦¬ì—ì„œ ë¯¸ê°œì²™ëœ ì—¬ì„± ê³ ê°ì¸µì„ íƒ€ê²Ÿìœ¼ë¡œ í•©ë‹ˆë‹¤. ì´ë“¤ì€ ëŒ€ì²´ë¡œ ë” ë¶€ìœ í•œ ì—¬ì„±ë“¤ì´ì§€ë§Œ, ì „ì‹  ë§ˆì·¨, íšŒë³µ ê¸°ê°„ ì¸¡ë©´ì—ì„œ ë§ì€ ì¥ë²½ë“¤ë„ ì¡´ì¬í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ ì‹œìˆ ì€ ë°”ë¡œ ê·¸ëŸ¬í•œ ìœ í˜•ì˜ ì†Œë¹„ìë“¤ì„ íƒ€ê²Ÿìœ¼ë¡œ í•©ë‹ˆë‹¤. ì €í¬ê°€ ì‹¤ì‹œí•œ ì¼ë¶€ ì‹œì¥ ì¡°ì‚¬ì—ì„œ, PreservÃ©ë¥¼ ì ‘í•œ í™˜ì 4ëª… ì¤‘ 1ëª…ì´ ìœ ë°© í™•ëŒ€ìˆ ì„ ë°›ì„ ì˜í–¥ì´ ìˆê±°ë‚˜ ê´€ì‹¬ì„ ë³´ì˜€ìœ¼ë©°, ì´ë“¤ ì—¬ì„±ì˜ 83%ê°€ PreservÃ© ì‹œìˆ ì„ ì›í•œë‹¤ëŠ” ê²°ê³¼ë¥¼ í™•ì¸í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>What we're also learning is that most patients -- almost all patients that do PreservÃ©, what is an opportunity for us, not only for us as a business, but also the surgeons is they're willing to pay a premium. So in the U.S., with the early experience surgeons, the 50 early experience surgeons, on average, they are -- patients are spending up to 20% more than traditional augmentation, in some cases, up to 40%. What we're also hearing in terms from the early experience surgeons is that patients are actually traveling to different parts of the U.S. because it's only limited in the number of locations to do PreservÃ© surgeries.</td><td>ìš°ë¦¬ê°€ ë˜í•œ ì•Œê²Œ ëœ ê²ƒì€ ëŒ€ë¶€ë¶„ì˜ í™˜ìë“¤, ê±°ì˜ ëª¨ë“  PreservÃ© ì‹œìˆ ì„ ë°›ëŠ” í™˜ìë“¤ì´ í”„ë¦¬ë¯¸ì—„ ê°€ê²©ì„ ê¸°êº¼ì´ ì§€ë¶ˆí•œë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ ë¹„ì¦ˆë‹ˆìŠ¤ë¿ë§Œ ì•„ë‹ˆë¼ ì™¸ê³¼ì˜ë“¤ì—ê²Œë„ ê¸°íšŒê°€ ë©ë‹ˆë‹¤. ë¯¸êµ­ì—ì„œ ì´ˆê¸° ê²½í—˜ ì™¸ê³¼ì˜ 50ëª…ì˜ ê²½ìš°, í‰ê· ì ìœ¼ë¡œ í™˜ìë“¤ì´ ê¸°ì¡´ ë³´í˜•ë¬¼ ìˆ˜ìˆ ë³´ë‹¤ ìµœëŒ€ 20%, ê²½ìš°ì— ë”°ë¼ì„œëŠ” ìµœëŒ€ 40%ê¹Œì§€ ë” ë§ì€ ë¹„ìš©ì„ ì§€ì¶œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì´ˆê¸° ê²½í—˜ ì™¸ê³¼ì˜ë“¤ë¡œë¶€í„° ë“£ê³  ìˆëŠ” ê²ƒì€, PreservÃ© ìˆ˜ìˆ ì„ í•  ìˆ˜ ìˆëŠ” ì¥ì†Œê°€ ì œí•œì ì´ê¸° ë•Œë¬¸ì— í™˜ìë“¤ì´ ì‹¤ì œë¡œ ë¯¸êµ­ ë‚´ ë‹¤ë¥¸ ì§€ì—­ìœ¼ë¡œ ì´ë™í•˜ì—¬ ì‹œìˆ ì„ ë°›ê³  ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And also, we're hearing from those surgeons that it's actually bringing in more volume and more business. So we fully expect that once we roll this out, that it has an opportunity to drive category growth for Motiva. Now as I mentioned, we expect to do over $30 million in revenue in 2026. We already launched PreservÃ© outside the U.S., first in Brazil, rolled that out to Europe, and we're in 29 markets, global markets. It's a key driver for our growth in 2025, and we expect that in 2026, especially in our direct markets. And we expect a formal launch in the end of Q1 2026 in the U.S. Now Mia, we continue to have very good growth in EMEA. It's much more on the premium segment.</td><td>ë˜í•œ ì™¸ê³¼ì˜ë“¤ë¡œë¶€í„° ì‹¤ì œë¡œ ë” ë§ì€ ìˆ˜ìˆ  ê±´ìˆ˜ì™€ ë§¤ì¶œì„ ê°€ì ¸ì˜¤ê³  ìˆë‹¤ëŠ” í”¼ë“œë°±ì„ ë°›ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ë¥¼ ì „ë©´ ì¶œì‹œí•˜ë©´ Motivaì˜ ì¹´í…Œê³ ë¦¬ ì„±ì¥ì„ ê²¬ì¸í•  ê¸°íšŒê°€ ìˆì„ ê²ƒìœ¼ë¡œ ì¶©ë¶„íˆ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, 2026ë…„ì— 3ì²œë§Œ ë‹¬ëŸ¬ ì´ìƒì˜ ë§¤ì¶œì„ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ë¯¸ ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œ PreservÃ©ë¥¼ ì¶œì‹œí–ˆìœ¼ë©°, ë¨¼ì € ë¸Œë¼ì§ˆì—ì„œ ì‹œì‘í•˜ì—¬ ìœ ëŸ½ìœ¼ë¡œ í™•ëŒ€í–ˆê³ , í˜„ì¬ ì „ ì„¸ê³„ 29ê°œ ì‹œì¥ì— ì§„ì¶œí•´ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” 2025ë…„ ì„±ì¥ì˜ í•µì‹¬ ë™ë ¥ì´ë©°, íŠ¹íˆ ì§ì ‘ íŒë§¤ ì‹œì¥ì—ì„œ 2026ë…„ì—ë„ ê·¸ëŸ´ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  2026ë…„ 1ë¶„ê¸° ë§ì— ë¯¸êµ­ì—ì„œ ì •ì‹ ì¶œì‹œí•  ì˜ˆì •ì…ë‹ˆë‹¤. Miaì˜ ê²½ìš°, EMEA ì§€ì—­ì—ì„œ ì§€ì†ì ìœ¼ë¡œ ë§¤ìš° ì¢‹ì€ ì„±ì¥ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” í”„ë¦¬ë¯¸ì—„ ì„¸ê·¸ë¨¼íŠ¸ì— í›¨ì”¬ ë” ì§‘ì¤‘ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>It's a transactionary approach. There is no scar on the breast. And we've doubled the number of accounts through our franchise model. We continue to see good growth as PreservÃ© comes underneath and really expands the market as well. Now we see a significant opportunity, leveraging the minimally invasive technology with the gluteal implants. This is a market that we believe is very underdeveloped. The current solutions are high risk and not the best outcome. So we really believe with our technology that we can leverage that, provide patients with a superior outcome, but also a safer alternative. Right now, we're doing clinical studies in Latin America.</td><td>ì´ëŠ” ê²½í”¼ì  ì ‘ê·¼ë²•ì…ë‹ˆë‹¤. ìœ ë°©ì— í‰í„°ê°€ ë‚¨ì§€ ì•ŠìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” í”„ëœì°¨ì´ì¦ˆ ëª¨ë¸ì„ í†µí•´ ê±°ë˜ì²˜ ìˆ˜ë¥¼ ë‘ ë°°ë¡œ ëŠ˜ë ¸ìŠµë‹ˆë‹¤. PreservÃ©ê°€ í•©ë¥˜í•˜ë©´ì„œ ì‹œì¥ì„ ì‹¤ì§ˆì ìœ¼ë¡œ í™•ëŒ€í•˜ëŠ” ê°€ìš´ë° ì§€ì†ì ìœ¼ë¡œ ì¢‹ì€ ì„±ì¥ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ìš°ë¦¬ëŠ” ë‘”ë¶€ ì„í”Œë€íŠ¸ì™€ í•¨ê»˜ ìµœì†Œì¹¨ìŠµ ê¸°ìˆ ì„ í™œìš©í•  ìˆ˜ ìˆëŠ” ìƒë‹¹í•œ ê¸°íšŒë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì€ ë§¤ìš° ì €ê°œë°œëœ ì‹œì¥ì´ë¼ê³  ë¯¿ìŠµë‹ˆë‹¤. í˜„ì¬ì˜ ì†”ë£¨ì…˜ë“¤ì€ ê³ ìœ„í—˜ì´ë©° ìµœì„ ì˜ ê²°ê³¼ë¥¼ ì œê³µí•˜ì§€ ëª»í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ìš°ë¦¬ì˜ ê¸°ìˆ ë¡œ ì´ë¥¼ í™œìš©í•˜ì—¬ í™˜ìë“¤ì—ê²Œ ìš°ìˆ˜í•œ ê²°ê³¼ë¿ë§Œ ì•„ë‹ˆë¼ ë” ì•ˆì „í•œ ëŒ€ì•ˆì„ ì œê³µí•  ìˆ˜ ìˆë‹¤ê³  í™•ì‹ í•©ë‹ˆë‹¤. í˜„ì¬ ìš°ë¦¬ëŠ” ë¼í‹´ ì•„ë©”ë¦¬ì¹´ì—ì„œ ì„ìƒ ì—°êµ¬ë¥¼ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We expect that the first launch will be in 2027 in Latin America. And depending on the regulatory framework and our rollout timing, we'll be looking at rolling this out in the U.S. and Europe and Asia as well in the coming years. So a key driver for us as a business, the minimally invasive platform. We're off to a very good start in OUS markets, but that will continue in 2026 and beyond. Now there's a number of market tailwinds out there. Everybody talks about the GLP-1s A lot of the surgeons that we're engaged with tell us that a number of women are coming in, doing and looking at breast augmentation procedures based on the impact of GLP-1s.</td><td>2027ë…„ ë¼í‹´ ì•„ë©”ë¦¬ì¹´ì—ì„œ ì²« ì¶œì‹œê°€ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ê·œì œ í”„ë ˆì„ì›Œí¬ì™€ ì¶œì‹œ ì¼ì •ì— ë”°ë¼, í–¥í›„ ëª‡ ë…„ê°„ ë¯¸êµ­, ìœ ëŸ½, ì•„ì‹œì•„ì—ì„œë„ ì¶œì‹œë¥¼ ê²€í† í•  ì˜ˆì •ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ìµœì†Œì¹¨ìŠµ í”Œë«í¼ì€ ìš°ë¦¬ ì‚¬ì—…ì˜ í•µì‹¬ ë™ë ¥ì…ë‹ˆë‹¤. í•´ì™¸ ì‹œì¥ì—ì„œ ë§¤ìš° ì¢‹ì€ ì¶œë°œì„ ë³´ì˜€ìœ¼ë©°, ì´ëŠ” 2026ë…„ê³¼ ê·¸ ì´í›„ì—ë„ ê³„ì†ë  ê²ƒì…ë‹ˆë‹¤.<br><br>í˜„ì¬ ì‹œì¥ì—ëŠ” ì—¬ëŸ¬ ìˆœí’ ìš”ì¸ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ëª¨ë‘ê°€ GLP-1ì— ëŒ€í•´ ì´ì•¼ê¸°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ í˜‘ë ¥í•˜ê³  ìˆëŠ” ë§ì€ ì™¸ê³¼ì˜ì‚¬ë“¤ì€ GLP-1ì˜ ì˜í–¥ìœ¼ë¡œ ì¸í•´ ë§ì€ ì—¬ì„±ë“¤ì´ ìœ ë°©í™•ëŒ€ìˆ ì„ ì°¾ì•„ì˜¤ê³  ìˆë‹¤ê³  ë§í•©ë‹ˆë‹¤.</td></tr>
<tr><td>But another key driver, and some of this is driven by us with our celebrity endorsements, a lot of the social media that we're doing is really creating an era of transparency. People celebrities are coming out talking about their -- the augmentations. People are much more public about having breast augmentations and really reducing a lot of the stigma that was really impacting the potential growth for the augmentation market. And we're also seeing a lot of mainstream media talking about breast augmentations. You have the Wall Street Journal, you have the Washington Post talking about smaller sizes, more natural outcomes.</td><td>í•˜ì§€ë§Œ ë˜ ë‹¤ë¥¸ í•µì‹¬ ë™ì¸ì€, ê·¸ë¦¬ê³  ì´ ì¤‘ ì¼ë¶€ëŠ” ìš°ë¦¬ì˜ ìœ ëª…ì¸ í™ë³´ í™œë™ì— ì˜í•´ ì£¼ë„ë˜ê³  ìˆëŠ”ë°, ìš°ë¦¬ê°€ ì§„í–‰í•˜ê³  ìˆëŠ” ë§ì€ ì†Œì…œ ë¯¸ë””ì–´ í™œë™ë“¤ì´ ì‹¤ì œë¡œ íˆ¬ëª…ì„±ì˜ ì‹œëŒ€ë¥¼ ë§Œë“¤ì–´ë‚´ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ìœ ëª…ì¸ë“¤ì´ ë‚˜ì„œì„œ ìì‹ ë“¤ì˜ ë³´í˜•ë¬¼ ì‹œìˆ ì— ëŒ€í•´ ì´ì•¼ê¸°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‚¬ëŒë“¤ì´ ìœ ë°©í™•ëŒ€ìˆ ì„ ë°›ì€ ê²ƒì— ëŒ€í•´ í›¨ì”¬ ë” ê³µê°œì ìœ¼ë¡œ ì´ì•¼ê¸°í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì‹¤ì œë¡œ ìœ ë°©í™•ëŒ€ ì‹œì¥ì˜ ì ì¬ì  ì„±ì¥ì— ì˜í–¥ì„ ë¯¸ì³¤ë˜ ë§ì€ ì‚¬íšŒì  ë‚™ì¸ì„ ì¤„ì´ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ìš°ë¦¬ëŠ” ë§ì€ ì£¼ë¥˜ ì–¸ë¡ ë“¤ì´ ìœ ë°©í™•ëŒ€ìˆ ì— ëŒ€í•´ ë‹¤ë£¨ëŠ” ê²ƒì„ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì›”ìŠ¤íŠ¸ë¦¬íŠ¸ì €ë„, ì›Œì‹±í„´í¬ìŠ¤íŠ¸ê°€ ë” ì‘ì€ ì‚¬ì´ì¦ˆ, ë” ìì—°ìŠ¤ëŸ¬ìš´ ê²°ê³¼ì— ëŒ€í•´ ì´ì•¼ê¸°í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So significant tailwinds that I think will continue to drive the market. But as I said before, a lot of this is driven by a lot of the marketing efforts that we're doing as well. Now talking about 2027 and beyond. We have a significant innovation pipeline. So it's not just about 2026. We see double-digit growth or over 25% growth in the next 2 years in 2027 and beyond. You look at the real impact that we believe that we're going to have for the breast recon indication will be in 2027, the real commercial impact. Then we talk about continuing to expand the global footprint for the minimally invasive platform.</td><td>ì €í¬ê°€ ìƒê°í•˜ê¸°ì— ì‹œì¥ì„ ì§€ì†ì ìœ¼ë¡œ ê²¬ì¸í•  ì¤‘ìš”í•œ ìˆœí’ë“¤ì´ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì•ì„œ ë§ì”€ë“œë ¸ë“¯ì´, ì´ ì¤‘ ìƒë‹¹ ë¶€ë¶„ì€ ì €í¬ê°€ ì§„í–‰í•˜ê³  ìˆëŠ” ë§ˆì¼€íŒ… í™œë™ë“¤ì— ì˜í•´ ì£¼ë„ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ 2027ë…„ ì´í›„ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ìƒë‹¹í•œ í˜ì‹  íŒŒì´í”„ë¼ì¸ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ê²ƒì€ ë‹¨ì§€ 2026ë…„ë§Œì˜ ì´ì•¼ê¸°ê°€ ì•„ë‹™ë‹ˆë‹¤. ì €í¬ëŠ” í–¥í›„ 2ë…„ê°„ì¸ 2027ë…„ ì´í›„ì—ë„ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ë¥  ë˜ëŠ” 25% ì´ìƒì˜ ì„±ì¥ì„ ì „ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìœ ë°©ì¬ê±´ ì ì‘ì¦ì—ì„œ ì‹¤ì œë¡œ ë¯¸ì¹  ì˜í–¥ì„ ë³´ì‹œë©´, ì‹¤ì§ˆì ì¸ ìƒì—…ì  íš¨ê³¼ëŠ” 2027ë…„ì— ë‚˜íƒ€ë‚  ê²ƒìœ¼ë¡œ ì €í¬ëŠ” ë¯¿ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìµœì†Œì¹¨ìŠµ í”Œë«í¼ì˜ ê¸€ë¡œë²Œ ì…ì§€ë¥¼ ì§€ì†ì ìœ¼ë¡œ í™•ëŒ€í•˜ëŠ” ê²ƒì— ëŒ€í•´ì„œë„ ë§ì”€ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>In order to launch that in the U.S., we're going to be submitting a PMA supplement to be first half of this year. We're going to need to get the ERGO 2 approval in order to launch Mia. And then we talked about the GEM in 2027 and beyond once we start rolling that out in other geographies. But as a company, we're always going to be looking at different innovations. We're the only company in this space that focuses on innovation, and that's really the DNA of this company. And so really tremendous opportunities, really executing on what we have. There's a lot of close-in opportunities, but also in the outer years and leveraging this technology.</td><td>ë¯¸êµ­ì—ì„œ ì´ë¥¼ ì¶œì‹œí•˜ê¸° ìœ„í•´ ì˜¬í•´ ìƒë°˜ê¸°ì— PMA ë³´ì™„ ì‹ ì²­ì„œë¥¼ ì œì¶œí•  ì˜ˆì •ì…ë‹ˆë‹¤. Miaë¥¼ ì¶œì‹œí•˜ê¸° ìœ„í•´ì„œëŠ” ERGO 2 ìŠ¹ì¸ì„ ë°›ì•„ì•¼ í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  2027ë…„ ì´í›„ ë‹¤ë¥¸ ì§€ì—­ì—ì„œ ì¶œì‹œë¥¼ ì‹œì‘í•˜ë©´ì„œ GEMì— ëŒ€í•´ì„œë„ ë§ì”€ë“œë ¸ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ íšŒì‚¬ë¡œì„œ ìš°ë¦¬ëŠ” í•­ìƒ ë‹¤ì–‘í•œ í˜ì‹ ì„ ëª¨ìƒ‰í•  ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ ë¶„ì•¼ì—ì„œ í˜ì‹ ì— ì§‘ì¤‘í•˜ëŠ” ìœ ì¼í•œ íšŒì‚¬ì´ë©°, ì´ê²ƒì´ ë°”ë¡œ ì´ íšŒì‚¬ì˜ DNAì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì •ë§ ì—„ì²­ë‚œ ê¸°íšŒë“¤ì´ ìˆê³ , ìš°ë¦¬ê°€ ê°€ì§„ ê²ƒë“¤ì„ ì‹¤í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê°€ê¹Œìš´ ì‹œì¼ ë‚´ì˜ ê¸°íšŒë“¤ë„ ë§ì§€ë§Œ, í–¥í›„ ëª‡ ë…„ê°„ì˜ ê¸°íšŒë“¤ë„ ìˆìœ¼ë©° ì´ ê¸°ìˆ ì„ í™œìš©í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Now as we continue to grow, and we're very well positioned to drive incremental profitability over the next couple of years. When you look at our revenue, we're expecting to grow at least 25% over the next 2 years. But our -- if you look at our corporate infrastructure, has really already been built. So we have enough capacity from a manufacturing standpoint to do -- to supply over 50% of the global market. A lot of our corporate roles and our corporate functions are already established. So really, as we drive the revenue, it doesn't require as much investment to maintain or to support the revenue growth. As I mentioned, in this year, we broke the 70% gross margin mark.</td><td>ì €í¬ê°€ ê³„ì† ì„±ì¥í•˜ë©´ì„œ, í–¥í›„ 2ë…„ê°„ ì ì§„ì ì¸ ìˆ˜ìµì„± ê°œì„ ì„ ì´ëŒì–´ë‚¼ ìˆ˜ ìˆëŠ” ë§¤ìš° ìœ ë¦¬í•œ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. ë§¤ì¶œì„ ë³´ì‹œë©´, í–¥í›„ 2ë…„ê°„ ìµœì†Œ 25% ì„±ì¥ì„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ê¸°ì—… ì¸í”„ë¼ëŠ” ì´ë¯¸ êµ¬ì¶•ì´ ì™„ë£Œëœ ìƒíƒœì…ë‹ˆë‹¤. ì œì¡° ê´€ì ì—ì„œ ë³´ë©´ ì „ ì„¸ê³„ ì‹œì¥ì˜ 50% ì´ìƒì„ ê³µê¸‰í•  ìˆ˜ ìˆëŠ” ì¶©ë¶„í•œ ìƒì‚°ëŠ¥ë ¥ì„ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤. ê¸°ì—… ì¡°ì§ê³¼ ê¸°ì—… ê¸°ëŠ¥ì˜ ìƒë‹¹ ë¶€ë¶„ë„ ì´ë¯¸ í™•ë¦½ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë§¤ì¶œ ì„±ì¥ì„ ì¶”ì§„í•˜ëŠ” ë° ìˆì–´ì„œ ì´ë¥¼ ìœ ì§€í•˜ê±°ë‚˜ ë’·ë°›ì¹¨í•˜ê¸° ìœ„í•œ íˆ¬ìê°€ ê·¸ë§Œí¼ ë§ì´ í•„ìš”í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ì˜¬í•´ ë§¤ì¶œì´ì´ìµë¥  70%ë¥¼ ëŒíŒŒí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And I think that's going to continue to drive growth or continue to increase as we launch the minimally invasive platform as we continue to grow in the U.S. and also as we get the recon indication. So significant margin expansion we expect in the coming years. And it's also a lot of our discipline in terms of how we manage the business. We've been very successful in getting to EBITDA positive. We're on track to achieve cash flow positive in 2026 by really implementing a lot of the discipline that enable us to get to this point. So in summary, as I mentioned before, 2025 was a great year for Establishment Labs, but we're really well positioned for 2026 and beyond.</td><td>ê·¸ë¦¬ê³  ì´ëŠ” ìµœì†Œì¹¨ìŠµ í”Œë«í¼ì„ ì¶œì‹œí•˜ê³  ë¯¸êµ­ì—ì„œ ì§€ì†ì ìœ¼ë¡œ ì„±ì¥í•˜ë©° ì¬ê±´ ì ì‘ì¦ì„ íšë“í•¨ì— ë”°ë¼ ê³„ì†í•´ì„œ ì„±ì¥ì„ ê²¬ì¸í•˜ê±°ë‚˜ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ë”°ë¼ì„œ í–¥í›„ ëª‡ ë…„ê°„ ìƒë‹¹í•œ ë§ˆì§„ í™•ëŒ€ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ë˜í•œ ì‚¬ì—… ê´€ë¦¬ ë°©ì‹ì— ëŒ€í•œ ìš°ë¦¬ì˜ ê·œìœ¨ì˜ ê²°ê³¼ì´ê¸°ë„ í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” EBITDA í‘ì ë‹¬ì„±ì— ë§¤ìš° ì„±ê³µì ì´ì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ ì´ ì§€ì ì— ë„ë‹¬í•  ìˆ˜ ìˆê²Œ í•œ ë§ì€ ê·œìœ¨ì„ ì‹¤ì œë¡œ êµ¬í˜„í•¨ìœ¼ë¡œì¨ 2026ë…„ í˜„ê¸ˆíë¦„ í‘ì ë‹¬ì„± ëª©í‘œë¥¼ ìˆœì¡°ë¡­ê²Œ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš”ì•½í•˜ìë©´, ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ 2025ë…„ì€ Establishment Labsì—ê²Œ í›Œë¥­í•œ í•œ í•´ì˜€ì§€ë§Œ, ìš°ë¦¬ëŠ” 2026ë…„ê³¼ ê·¸ ì´í›„ë¥¼ ìœ„í•´ ë§¤ìš° ì¢‹ì€ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We are the leaders in terms of breast aesthetics and reconstruction. We're setting the standards. We continue to evolve with our innovation to drive the category. You're seeing significant growth in the U.S. We've accomplished significant share from the standpoint of our exit velocity, and we expect that to continue to grow. And then we're also going to be rolling out the minimally invasive platform, which has a tremendous opportunity for us to drive share as well as expand the market -- we are seeing the tailwinds in terms of the GLP-1s, the era of transparency, much more openness around breast augmentation.</td><td>ì €í¬ëŠ” ìœ ë°© ë¯¸ìš© ë° ì¬ê±´ ë¶„ì•¼ì˜ ì„ ë‘ì£¼ìì…ë‹ˆë‹¤. ì €í¬ê°€ ì—…ê³„ í‘œì¤€ì„ ì •ë¦½í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜ì‹ ì„ í†µí•´ ì´ ì¹´í…Œê³ ë¦¬ë¥¼ ì§€ì†ì ìœ¼ë¡œ ë°œì „ì‹œí‚¤ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ì—ì„œ ìƒë‹¹í•œ ì„±ì¥ì„¸ë¥¼ ë³´ì´ê³  ìˆìœ¼ë©°, ì¶œêµ¬ ì†ë„(exit velocity) ê´€ì ì—ì„œ ìƒë‹¹í•œ ì‹œì¥ì ìœ ìœ¨ì„ í™•ë³´í–ˆê³ , ì´ëŸ¬í•œ ì„±ì¥ì„¸ê°€ ì§€ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë˜í•œ ìµœì†Œì¹¨ìŠµ í”Œë«í¼ì„ ì¶œì‹œí•  ì˜ˆì •ì¸ë°, ì´ëŠ” ì‹œì¥ì ìœ ìœ¨ í™•ëŒ€ëŠ” ë¬¼ë¡  ì‹œì¥ ìì²´ë¥¼ í™•ì¥í•  ìˆ˜ ìˆëŠ” ì—„ì²­ë‚œ ê¸°íšŒê°€ ë  ê²ƒì…ë‹ˆë‹¤. GLP-1 ì•½ë¬¼ì˜ ìˆœí’, íˆ¬ëª…ì„±ì˜ ì‹œëŒ€, ìœ ë°©í™•ëŒ€ìˆ ì— ëŒ€í•œ í›¨ì”¬ ë” ê°œë°©ì ì¸ ë¶„ìœ„ê¸° ë“±ì˜ í˜¸ì¬ë¥¼ ê²½í—˜í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And then we have really established an infrastructure that can support our business. We expect to have very sizable profits moving forward. So that's a summary, very exciting time in Establishment Labs. And I guess, Allen, now it's a Q&A.</td><td>ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ì‚¬ì—…ì„ ì§€ì›í•  ìˆ˜ ìˆëŠ” ì¸í”„ë¼ë¥¼ ì‹¤ì œë¡œ êµ¬ì¶•í–ˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œ ë§¤ìš° ìƒë‹¹í•œ ê·œëª¨ì˜ ì´ìµì„ ë‚¼ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ê²ƒì´ ìš”ì•½ì…ë‹ˆë‹¤. Establishment Labsì—ê²Œ ë§¤ìš° í¥ë¯¸ì§„ì§„í•œ ì‹œê¸°ì…ë‹ˆë‹¤. Allen, ì´ì œ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì¸ ê²ƒ ê°™ìŠµë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Establishment Labs (ESTA) J.P. Morgan ì»¨í¼ëŸ°ìŠ¤ ìš”ì•½<br><br>## í•µì‹¬ í¬ì¸íŠ¸<br><br>â€¢ **ê°•ë ¥í•œ 2025ë…„ ì‹¤ì  ë° ë¯¸êµ­ ì‹œì¥ ì„±ê³µ**: 2025ë…„ ê¸€ë¡œë²Œ ë§¤ì¶œ 27% ì„±ì¥í•˜ì—¬ $210.5~211.5M ë‹¬ì„±. ë¯¸êµ­ ì‹œì¥ ì²« í•´ ë§¤ì¶œ $45M ì´ˆê³¼ë¡œ ì—…ê³„ ìµœê³  ì†ë„ì˜ ëŸ°ì¹­ ê¸°ë¡. 2025ë…„ ë§ ë¯¸êµ­ ì‹œì¥ì ìœ ìœ¨ ì•½ 20%ë¡œ ì¶”ì •ë˜ë©°, 1,500ê°œ ì´ìƒ ê±°ë˜ì²˜ í™•ë³´. Q3ë¶€í„° EBITDA í‘ì ì „í™˜í•˜ê³  í˜„ê¸ˆ ì”ê³  $75.5Mìœ¼ë¡œ ì „ë¶„ê¸° ëŒ€ë¹„ $5M ì¦ê°€.<br><br>â€¢ **ì°¨ë³„í™”ëœ ì œí’ˆ ê²½ìŸë ¥**: Motiva ì„í”Œë€íŠ¸ëŠ” 4ê°œ íŠ¹í—ˆ ê¸°ìˆ  ë³´ìœ ë¡œ FDA ì„ìƒ 5ë…„ ë°ì´í„°ì—ì„œ ê¸°ê¸° ê´€ë ¨ í•©ë³‘ì¦ 1% ë¯¸ë§Œ ê¸°ë¡ (ê²½ìŸì‚¬ ëŒ€ë¹„ ìµœëŒ€ 10ë°° ë‚®ìŒ). 92ì–µ íšŒ ì´ìƒì˜ ë§ˆì¼€íŒ… ë…¸ì¶œê³¼ ìœ ëª…ì¸ í˜‘ì°¬(Meghan Trainor)ì„ í†µí•´ í™˜ìë“¤ì´ ë¸Œëœë“œë¥¼ ì§ì ‘ ì§€ëª…í•˜ëŠ” ìµœì´ˆ ì‚¬ë¡€ ì°½ì¶œ.<br><br>â€¢ **ì„±ì¥ ë™ë ¥ ë° 2026ë…„ ì „ë§**: ìµœì†Œì¹¨ìŠµ í”Œë«í¼ PreservÃ©ê°€ 2026ë…„ $30M+ ë§¤ì¶œ ê¸°ì—¬ ì˜ˆìƒ. ì¬ê±´(recon) ì ì‘ì¦ PMA ì œì¶œ ì™„ë£Œë¡œ ë¯¸êµ­ ì‹œì¥ 2ë°° í™•ëŒ€ ê°€ëŠ¥ì„± (ì¬ê±´ ì‹œì¥ ê·œëª¨ê°€ ë¯¸ìš© ì‹œì¥ê³¼ ë™ì¼). í–¥í›„</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>K. Gong: JPMorgan Chase & Co, Research Division Thanks for that, Peter. So I think I just want to start with the quarter that you just talked about. You already talked about it in the presentation, but put up a really good performance, $64 million to $65 million in the quarter, give or take. And the U.S. really kind of hitting the growth from third quarter to fourth quarter that I think we were really hoping to look at. But I guess just like taking it from a high level at first, when we think about the health of the underlying market, obviously, you were able to drive the growth that you're looking for in the U.S. market. You've talked about how there's market trends between GLP-1s, between social media that are continuing to support your growth. But how do you think about the overall health of the broader market when it comes to consumer spending and the durability of that into 2026?</td><td>**K. Gong:** í”¼í„°, ë‹µë³€ ê°ì‚¬í•©ë‹ˆë‹¤. ë°©ê¸ˆ ë§ì”€í•˜ì‹  ë¶„ê¸° ì‹¤ì ë¶€í„° ì‹œì‘í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ë°œí‘œì—ì„œ ì´ë¯¸ ì–¸ê¸‰í•˜ì…¨ì§€ë§Œ, ë¶„ê¸°ì— 6,400ë§Œ ë‹¬ëŸ¬ì—ì„œ 6,500ë§Œ ë‹¬ëŸ¬ ì •ë„ì˜ ì •ë§ ì¢‹ì€ ì‹¤ì ì„ ê¸°ë¡í•˜ì…¨ìŠµë‹ˆë‹¤. íŠ¹íˆ ë¯¸êµ­ ì‹œì¥ì´ 3ë¶„ê¸°ì—ì„œ 4ë¶„ê¸°ë¡œ ë„˜ì–´ê°€ë©´ì„œ ì €í¬ê°€ ê¸°ëŒ€í–ˆë˜ ì„±ì¥ì„¸ë¥¼ ë³´ì—¬ì£¼ì…¨ìŠµë‹ˆë‹¤. ìš°ì„  ë†’ì€ ìˆ˜ì¤€ì—ì„œ ë³´ë©´, ê¸°ì € ì‹œì¥ì˜ ê±´ì „ì„±ì— ëŒ€í•´ ìƒê°í•´ë³¼ ë•Œ, ë¶„ëª…íˆ ë¯¸êµ­ ì‹œì¥ì—ì„œ ëª©í‘œí•˜ì‹  ì„±ì¥ì„ ë‹¬ì„±í•˜ì…¨ìŠµë‹ˆë‹¤. GLP-1 ì˜ì•½í’ˆê³¼ ì†Œì…œ ë¯¸ë””ì–´ ê°„ì˜ ì‹œì¥ íŠ¸ë Œë“œê°€ ê³„ì†í•´ì„œ ê·€ì‚¬ì˜ ì„±ì¥ì„ ë’·ë°›ì¹¨í•˜ê³  ìˆë‹¤ê³  ë§ì”€í•˜ì…¨ëŠ”ë°ìš”. 2026ë…„ê¹Œì§€ ì†Œë¹„ì ì§€ì¶œê³¼ ê·¸ ì§€ì†ì„± ì¸¡ë©´ì—ì„œ ì „ë°˜ì ì¸ ì‹œì¥ ê±´ì „ì„±ì„ ì–´ë–»ê²Œ ë³´ê³  ê³„ì‹ ê°€ìš”?</td></tr>
<tr><td>CEO & Director: Yes. I mean I think when you look at it on a global basis, specific to breast implants, I mean, we've seen it's a relatively stable market in most of the geographies in which we compete. So for us, with that stability and as we keep on driving share growth through our minimally invasive platform as well as what we're doing in the U.S. in terms of expanding our sales force, the smaller sizes, I think we really have an opportunity to continue to drive growth. And we don't see any issues or concerns regarding the macroeconomic environment as it relates to its impact on implants.</td><td>**CEO & Director:** ë„¤, ê¸€ë¡œë²Œ ê¸°ì¤€ìœ¼ë¡œ ë³´ë©´, íŠ¹íˆ ìœ ë°© ë³´í˜•ë¬¼(breast implants)ì˜ ê²½ìš° ì €í¬ê°€ ê²½ìŸí•˜ê³  ìˆëŠ” ëŒ€ë¶€ë¶„ì˜ ì§€ì—­ì—ì„œ ë¹„êµì  ì•ˆì •ì ì¸ ì‹œì¥ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŸ¬í•œ ì•ˆì •ì„±ì„ ë°”íƒ•ìœ¼ë¡œ ìµœì†Œ ì¹¨ìŠµ í”Œë«í¼ì„ í†µí•œ ì‹œì¥ ì ìœ ìœ¨ í™•ëŒ€ë¥¼ ì§€ì†ì ìœ¼ë¡œ ì¶”ì§„í•˜ê³  ìˆìœ¼ë©°, ë¯¸êµ­ì—ì„œëŠ” ì˜ì—… ì¸ë ¥ í™•ì¶©ê³¼ ì†Œí˜• ì‚¬ì´ì¦ˆ ì œí’ˆ ì¶œì‹œë¥¼ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ì§€ì†ì ì¸ ì„±ì¥ì„ ì´ëŒì–´ë‚¼ ìˆ˜ ìˆëŠ” ì¶©ë¶„í•œ ê¸°íšŒê°€ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê±°ì‹œê²½ì œ í™˜ê²½ì´ ë³´í˜•ë¬¼ ì‚¬ì—…ì— ë¯¸ì¹˜ëŠ” ì˜í–¥ê³¼ ê´€ë ¨í•´ì„œëŠ” ì–´ë– í•œ ìš°ë ¤ ì‚¬í•­ë„ ì—†ë‹¤ê³  íŒë‹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>K. Gong: JPMorgan Chase & Co, Research Division I guess internationally, so you didn't break it out, but clearly, based on the performance internationally as a whole, you did in line to better than expected. you break out your international markets into 3 segments. So when we think about performances across Latin America, APAC, EMEA, there's been some market challenges there. You've been able to stabilize in some of your direct markets in third quarter. But have we seen that strength in direct markets continue into fourth quarter? What was distributor demand like? And if you could talk about just dynamics between the 3 different geographies.</td><td>**K. Gong:** êµ­ì œ ì‹œì¥ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ë³„ë„ë¡œ êµ¬ë¶„í•´ì„œ ë°œí‘œí•˜ì§€ëŠ” ì•Šì•˜ì§€ë§Œ ì „ì²´ì ì¸ êµ­ì œ ì‚¬ì—… ì‹¤ì ì„ ë³´ë©´ ë¶„ëª…íˆ ì˜ˆìƒì¹˜ì™€ ë¹„ìŠ·í•˜ê±°ë‚˜ ê·¸ ì´ìƒì˜ ì„±ê³¼ë¥¼ ê±°ë’€ìŠµë‹ˆë‹¤. ì €í¬ëŠ” êµ­ì œ ì‹œì¥ì„ 3ê°œ ë¶€ë¬¸ìœ¼ë¡œ ë‚˜ëˆ ì„œ ê´€ë¦¬í•˜ê³  ìˆëŠ”ë°ìš”. ë¼í‹´ì•„ë©”ë¦¬ì¹´, ì•„ì‹œì•„íƒœí‰ì–‘(APAC), ìœ ëŸ½Â·ì¤‘ë™Â·ì•„í”„ë¦¬ì¹´(EMEA) ì§€ì—­ì˜ ì‹¤ì ì„ ë³´ë©´, ì¼ë¶€ ì‹œì¥ì—ì„œ ì–´ë ¤ì›€ì´ ìˆì—ˆë˜ ê²ƒì´ ì‚¬ì‹¤ì…ë‹ˆë‹¤. 3ë¶„ê¸°ì— ì§ì ‘ ì§„ì¶œ ì‹œì¥ ì¼ë¶€ì—ì„œ ì•ˆì •í™”ë¥¼ ì´ë¤„ëƒˆëŠ”ë°ìš”. 4ë¶„ê¸°ì—ë„ ì´ëŸ¬í•œ ì§ì ‘ ì§„ì¶œ ì‹œì¥ì—ì„œì˜ ê°•ì„¸ê°€ ì§€ì†ë˜ì—ˆëŠ”ì§€, ìœ í†µì—…ì²´ ìˆ˜ìš”ëŠ” ì–´ë• ëŠ”ì§€, ê·¸ë¦¬ê³  ì„¸ ì§€ì—­ ê°„ì˜ ì—­í•™ ê´€ê³„ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>CEO & Director: Yes. So I'll talk about the direct and the distributor markets. I mean that was a strategic choice by us, Allen, to kind of really drive growth in the direct markets. These are markets we have much better economics. The price point is actually double than what we have in the distributor market. And quite frankly, we're probably a little bit too dependent on the distributor marketplace. So that was still in Q4, a key driver for our performance OUS. And over time, the plan is to continue to drive growth in those markets and really reduce our dependency on the distributor business. And in terms of the geographical breakout.</td><td>**CEO & Director:** ë„¤, ì§ì ‘ íŒë§¤ ì‹œì¥ê³¼ ìœ í†µì—…ì²´ ì‹œì¥ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. Allen, ì´ê±´ ì €í¬ê°€ ì „ëµì ìœ¼ë¡œ ì„ íƒí•œ ê²ƒì¸ë°ìš”, ì§ì ‘ íŒë§¤ ì‹œì¥ì—ì„œ ì„±ì¥ì„ ê²¬ì¸í•˜ê¸° ìœ„í•œ ê²ƒì…ë‹ˆë‹¤. ì´ ì‹œì¥ë“¤ì€ ê²½ì œì„±ì´ í›¨ì”¬ ë” ì¢‹ìŠµë‹ˆë‹¤. ê°€ê²©ëŒ€ê°€ ì‹¤ì œë¡œ ìœ í†µì—…ì²´ ì‹œì¥ë³´ë‹¤ ë‘ ë°° ì •ë„ ë˜ê±°ë“ ìš”. ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´, ì €í¬ê°€ ìœ í†µì—…ì²´ ì‹œì¥ì— ì¡°ê¸ˆ ê³¼ë„í•˜ê²Œ ì˜ì¡´í•˜ê³  ìˆì—ˆë˜ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ 4ë¶„ê¸°ì—ë„ ì´ê²Œ ì—¬ì „íˆ ë¯¸êµ­ ì™¸ ì§€ì—­ ì‹¤ì ì˜ í•µì‹¬ ë™ë ¥ì´ì—ˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œì˜ ê³„íšì€ ì´ëŸ° ì‹œì¥ë“¤ì—ì„œ ì§€ì†ì ìœ¼ë¡œ ì„±ì¥ì„ ì¶”ì§„í•˜ë©´ì„œ ìœ í†µì—…ì²´ ì‚¬ì—…ì— ëŒ€í•œ ì˜ì¡´ë„ë¥¼ ì‹¤ì§ˆì ìœ¼ë¡œ ì¤„ì—¬ë‚˜ê°€ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì§€ì—­ë³„ ì„¸ë¶€ ë‚´ì—­ì€ìš”.</td></tr>
<tr><td>Chief Financial Officer: Yes. I'd say, Allen, it's kind of in keeping with what we've seen over the balance of this year. As Peter noted, direct markets continue to drive the business for us. And if you think about within our segments, in Europe, we are split between distributors and direct. That market continues to do very well, again, driven by the health in the direct markets. Latin America is a bit of a mix as well. We're direct in Brazil and Argentina. We're seeing very good results in Argentina and our distributor markets there. Brazil has been a little challenging. We've talked about it, but we have seen stability in that market for the last several quarters. And then Asia Pacific is the one that is 100% distributor, right? And while we're seeing very good underlying trends in that business, there's always going to be that timing of orders, right? And so I'd say, overall, as Peter noted, the demand for our products globally remains very good, and we're seeing it across all the geographies.</td><td>**Chief Financial Officer:** ë„¤, Allen, ì˜¬í•´ ì „ë°˜ì ìœ¼ë¡œ ì €í¬ê°€ ë´ì˜¨ ê²ƒê³¼ ì¼ë§¥ìƒí†µí•œë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. Peterê°€ ì–¸ê¸‰í–ˆë“¯ì´, ì§ì ‘ ì‹œì¥ì´ ê³„ì†í•´ì„œ ì €í¬ ì‚¬ì—…ì„ ê²¬ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì„¸ê·¸ë¨¼íŠ¸ë³„ë¡œ ë³´ë©´, ìœ ëŸ½ì˜ ê²½ìš° ìœ í†µì—…ì²´ì™€ ì§ì ‘ íŒë§¤ë¡œ ë‚˜ë‰˜ì–´ ìˆìŠµë‹ˆë‹¤. í•´ë‹¹ ì‹œì¥ì€ ê³„ì†í•´ì„œ ë§¤ìš° ì¢‹ì€ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆìœ¼ë©°, ì´ëŠ” ë‹¤ì‹œ í•œë²ˆ ì§ì ‘ ì‹œì¥ì˜ ê±´ì „ì„±ì— ì˜í•´ ì£¼ë„ë˜ê³  ìˆìŠµë‹ˆë‹¤. ë¼í‹´ì•„ë©”ë¦¬ì¹´ë„ í˜¼í•©ëœ í˜•íƒœì…ë‹ˆë‹¤. ë¸Œë¼ì§ˆê³¼ ì•„ë¥´í—¨í‹°ë‚˜ì—ì„œëŠ” ì§ì ‘ íŒë§¤ë¥¼ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•„ë¥´í—¨í‹°ë‚˜ì™€ ê·¸ê³³ì˜ ìœ í†µì—…ì²´ ì‹œì¥ì—ì„œ ë§¤ìš° ì¢‹ì€ ì‹¤ì ì„ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë¸Œë¼ì§ˆì€ ë‹¤ì†Œ ì–´ë ¤ì›€ì´ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ì— ëŒ€í•´ ë§ì”€ë“œë¦° ë°” ìˆì§€ë§Œ, ì§€ë‚œ ëª‡ ë¶„ê¸° ë™ì•ˆ í•´ë‹¹ ì‹œì¥ì—ì„œ ì•ˆì •ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•„ì‹œì•„íƒœí‰ì–‘ì€ 100% ìœ í†µì—…ì²´ë¡œ ìš´ì˜ë˜ëŠ” ì§€ì—­ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  í•´ë‹¹ ì‚¬ì—…ì—ì„œ ë§¤ìš° ì¢‹ì€ ê¸°ì € íŠ¸ë Œë“œë¥¼ ë³´ê³  ìˆì§€ë§Œ, ì£¼ë¬¸ íƒ€ì´ë°ì´ë¼ëŠ” ê²ƒì€ í•­ìƒ ì¡´ì¬í•˜ì£ . ê·¸ë˜ì„œ ì „ë°˜ì ìœ¼ë¡œ í”¼í„°ê°€ ì–¸ê¸‰í–ˆë“¯ì´, ì „ ì„¸ê³„ì ìœ¼ë¡œ ìš°ë¦¬ ì œí’ˆì— ëŒ€í•œ ìˆ˜ìš”ëŠ” ì—¬ì „íˆ ë§¤ìš° ì¢‹ì€ ìƒíƒœì´ë©°, ëª¨ë“  ì§€ì—­ì—ì„œ ì´ë¥¼ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>K. Gong: JPMorgan Chase & Co, Research Division Okay. And then that 25% minimum of 25% in 2026, 2027, if I look at where consensus is today, they're right at the mid-20s or 2026. So it sounds like that's the floor to next year. What needs to -- at least implies that you see a path to upside. So what is the base case that gets you to 25%? And what needs to happen for you to outperform that?</td><td>**K. Gong:** ë„¤, 2026ë…„ê³¼ 2027ë…„ì˜ ìµœì†Œ 25% ëª©í‘œì— ëŒ€í•´ ë§ì”€ë“œë¦¬ìë©´, í˜„ì¬ ì»¨ì„¼ì„œìŠ¤ë¥¼ ë³´ë©´ 2026ë…„ì— ëŒ€ëµ 25% ì¤‘ë°˜ëŒ€ì— ìœ„ì¹˜í•´ ìˆìŠµë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ì´ê²ƒì´ ë‚´ë…„ì˜ í•˜í•œì„ ì´ ë˜ëŠ” ê²ƒìœ¼ë¡œ ë“¤ë¦¬ëŠ”ë°ìš”. ìµœì†Œí•œ ìƒìŠ¹ ì—¬ë ¥ì´ ìˆë‹¤ê³  ë³´ì‹œëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ 25%ë¥¼ ë‹¬ì„±í•˜ê¸° ìœ„í•œ ê¸°ë³¸ ì‹œë‚˜ë¦¬ì˜¤ëŠ” ë¬´ì—‡ì¸ê°€ìš”? ê·¸ë¦¬ê³  ì´ë¥¼ ìƒíšŒí•˜ëŠ” ì„±ê³¼ë¥¼ ë‚´ê¸° ìœ„í•´ì„œëŠ” ì–´ë–¤ ì¼ë“¤ì´ ì¼ì–´ë‚˜ì•¼ í• ê¹Œìš”?</td></tr>
<tr><td>Chief Financial Officer: Yes. I think if you again think about 27% growth we posted in 2025, right? So we're coming off a very strong year. We have a lot of momentum heading into 2026. what we need in order to make those numbers is just continue to execute. We haven't assumed any new product approvals. We haven't assumed reconstruction revenue in the United States in those numbers. So it's really a continuation of what we're currently doing. And so far, as I noted, we haven't picked up any change in the marketplace. The demand remains very good and what we're seeing in terms of the orders even here in early 2026 remains very good.</td><td>**Chief Financial Officer:** ë„¤, 2025ë…„ì— 27% ì„±ì¥ì„ ë‹¬ì„±í–ˆë‹¤ëŠ” ì ì„ ë‹¤ì‹œ ìƒê°í•´ë³´ì‹œë©´, ë§¤ìš° ê°•ë ¥í•œ í•œ í•´ë¥¼ ë³´ë‚¸ í›„ 2026ë…„ìœ¼ë¡œ ì§„ì…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìƒë‹¹í•œ ëª¨ë©˜í…€ì„ ê°€ì§€ê³  ìˆì£ . ëª©í‘œ ìˆ˜ì¹˜ë¥¼ ë‹¬ì„±í•˜ê¸° ìœ„í•´ í•„ìš”í•œ ê²ƒì€ í˜„ì¬ í•˜ê³  ìˆëŠ” ì¼ì„ ê³„ì† ì‹¤í–‰í•˜ëŠ” ê²ƒë¿ì…ë‹ˆë‹¤. ìƒˆë¡œìš´ ì œí’ˆ ìŠ¹ì¸ì€ ê°€ì •í•˜ì§€ ì•Šì•˜ê³ , ë¯¸êµ­ ë‚´ ì¬ê±´ ë§¤ì¶œ(reconstruction revenue)ë„ ì´ ìˆ˜ì¹˜ì— í¬í•¨í•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ì •ë§ í˜„ì¬ ì§„í–‰ ì¤‘ì¸ ì‚¬ì—…ì˜ ì—°ì†ì„ ìƒì— ìˆëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì œê°€ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ì§€ê¸ˆê¹Œì§€ ì‹œì¥ì—ì„œ ì–´ë–¤ ë³€í™”ë„ ê°ì§€í•˜ì§€ ëª»í–ˆìŠµë‹ˆë‹¤. ìˆ˜ìš”ëŠ” ì—¬ì „íˆ ë§¤ìš° ì¢‹ê³ , 2026ë…„ ì´ˆ í˜„ì¬ í™•ì¸ë˜ëŠ” ì£¼ë¬¸ ìƒí™©ë„ ë§¤ìš° ì–‘í˜¸í•©ë‹ˆë‹¤.</td></tr>
<tr><td>K. Gong: JPMorgan Chase & Co, Research Division The U.S. is definitely one of the major parts of the growth story going forward. You have tailwinds there next year between PreservÃ©, which is going to start launching or maybe has already started launching in the first quarter of this year and also just additional sizes, reconstruction, the reconstruction might be more 2027. So I guess starting on the augmentation side and especially with PreservÃ©, how much of a growth uplift do you think PreservÃ© can really add? And what is your approach to the launch this year, given it might be something a little bit more familiar for physicians at least compared to, say, like Mia? And how quickly can you really roll that out? And should we think of that as being potentially a workhorse, especially in the U.S. where your ASP compared to the rest of the world is already a little bit higher?</td><td>**K. Gong:** ë¯¸êµ­ì€ í™•ì‹¤íˆ í–¥í›„ ì„±ì¥ ìŠ¤í† ë¦¬ì˜ ì£¼ìš” ë¶€ë¶„ ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. ë‚´ë…„ì—ëŠ” PreservÃ©ê°€ ìˆëŠ”ë°, ì˜¬í•´ 1ë¶„ê¸°ì— ì¶œì‹œë¥¼ ì‹œì‘í–ˆê±°ë‚˜ ê³§ ì‹œì‘í•  ì˜ˆì •ì´ê³ , ì¶”ê°€ ì‚¬ì´ì¦ˆë“¤, ì¬ê±´ ë¶€ë¬¸ë„ ìˆìŠµë‹ˆë‹¤. ì¬ê±´ì€ 2027ë…„ì¯¤ì´ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤. ìš°ì„  í™•ëŒ€ ì‹œìˆ  ì¸¡ë©´ì—ì„œ, íŠ¹íˆ PreservÃ©ì™€ ê´€ë ¨í•´ì„œ ì§ˆë¬¸ë“œë¦¬ë©´, PreservÃ©ê°€ ì‹¤ì œë¡œ ì–¼ë§ˆë‚˜ í° ì„±ì¥ ìƒìŠ¹ íš¨ê³¼ë¥¼ ê°€ì ¸ì˜¬ ìˆ˜ ìˆë‹¤ê³  ë³´ì‹œëŠ”ì§€ìš”? ê·¸ë¦¬ê³  ì˜¬í•´ ì¶œì‹œ ì „ëµì€ ì–´ë–»ê²Œ ë˜ë‚˜ìš”? Mia ê°™ì€ ì œí’ˆì— ë¹„í•˜ë©´ ì˜ì‚¬ë“¤ì—ê²Œ ì¢€ ë” ìµìˆ™í•œ ì œí’ˆì¼ ìˆ˜ ìˆì„ ê²ƒ ê°™ì€ë°, ì–¼ë§ˆë‚˜ ë¹ ë¥´ê²Œ í™•ëŒ€ ì¶œì‹œí•  ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  íŠ¹íˆ ë¯¸êµ­ ì‹œì¥ì—ì„œ í•µì‹¬ ì£¼ë ¥ ì œí’ˆì´ ë  ê°€ëŠ¥ì„±ì´ ìˆë‹¤ê³  ë´ì•¼ í• ê¹Œìš”? ê·€ì‚¬ì˜ í‰ê·  íŒë§¤ ê°€ê²©(ASP)ì´ ì´ë¯¸ ë‹¤ë¥¸ ì§€ì—­ì— ë¹„í•´ ì¡°ê¸ˆ ë” ë†’ì€ ìƒí™©ì—ì„œ ë§ì”€í•˜ì‹œëŠ” ê±´ê°€ìš”?</td></tr>
<tr><td>CEO & Director: Yes. I mean I think the PreservÃ© launch is going to be a key driver for us, as I mentioned, not only to drive market share, but it's also -- there's a lot of indication that has the potential to expand the category. We're hearing that from the surgeons. And our rollout plan is really going to be focused on making sure we get the right education for the surgeons. So we expect that once we get that started, that it's going to really turn into a flywheel, and it's going to accelerate through the course of the year. But we expect a significant growth in 2026 on our PreservÃ© launch, but also the things that we're doing on our base augmentation when you're adding the additional sales reps, we've already got, as you highlighted, over 1,500 accounts. As we work through that utilization, the adoption curve, that's also going to continue to increase. So I think you're going to see it on both ends, the traditional augmentation as well as on the PreservÃ©.</td><td>**CEO & Director:** ë„¤, ë§ì”€ë“œë¦¬ìë©´ PreservÃ© ì¶œì‹œê°€ ì €í¬ì—ê²Œ í•µì‹¬ ì„±ì¥ ë™ë ¥ì´ ë  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì•ì„œ ì–¸ê¸‰í–ˆë“¯ì´ ì‹œì¥ ì ìœ ìœ¨ í™•ëŒ€ë¿ë§Œ ì•„ë‹ˆë¼ ì¹´í…Œê³ ë¦¬ ìì²´ë¥¼ í™•ì¥í•  ì ì¬ë ¥ì´ ìˆë‹¤ëŠ” ë§ì€ ì§•í›„ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ì§‘ë„ì˜ë“¤ë¡œë¶€í„° ì§ì ‘ ê·¸ëŸ° ì´ì•¼ê¸°ë¥¼ ë“£ê³  ìˆê³ ìš”. ì €í¬ ì¶œì‹œ ê³„íšì€ ì§‘ë„ì˜ë“¤ì—ê²Œ ì ì ˆí•œ êµìœ¡ì„ ì œê³µí•˜ëŠ” ë° ì§‘ì¤‘í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì¼ë‹¨ ì‹œì‘í•˜ë©´ í”Œë¼ì´íœ (flywheel) íš¨ê³¼ê°€ ë°œìƒí•´ì„œ ì—°ì¤‘ ë‚´ë‚´ ê°€ì†í™”ë  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. 2026ë…„ì—ëŠ” PreservÃ© ì¶œì‹œë¡œ ìƒë‹¹í•œ ì„±ì¥ì„ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ê¸°ì¡´ í™•ëŒ€(augmentation) ì‚¬ì—… ë¶€ë¬¸ì—ì„œë„ ì¶”ê°€ ì˜ì—… ì¸ë ¥ íˆ¬ì… ë“± ì—¬ëŸ¬ ì¡°ì¹˜ë¥¼ ì·¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ ì´ë¯¸ 1,500ê°œ ì´ìƒì˜ ê±°ë˜ì²˜ë¥¼ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. í™œìš©ë„ì™€ ë„ì… ê³¡ì„ ì„ ì§„í–‰í•´ ë‚˜ê°€ë©´ì„œ ì´ ë¶€ë¶„ë„ ê³„ì† ì¦ê°€í•  ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì „í†µì ì¸ í™•ëŒ€ìˆ ê³¼ PreservÃ© ì–‘ìª½ ëª¨ë‘ì—ì„œ ì„±ì¥ì„ ë³´ì‹¤ ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>K. Gong: JPMorgan Chase & Co, Research Division So diving a little bit deeper into that 1,500-plus number. I think in the past, you've talked about how when we look at -- when we focus on the higher volume customer base, there's only like a couple of thousand that really do the majority of procedures in the U.S. So when I think about 1,500, obviously, not every single one of those is going to be one of those high-volume surgeons, but you've clearly done a very good job of going broad and really making sure that you're getting into a lot of accounts -- so when I think about the growth outlook for 2026, how much of that is from going deeper into existing accounts? How much of that is going broader? Should we think about -- maybe a lot of those are the higher volume accounts, I would imagine, and now you're going to be adding on relatively smaller accounts. So just talk about that.</td><td>**K. Gong:** 1,500ê°œ ì´ìƒì´ë¼ëŠ” ìˆ«ìë¥¼ ì¢€ ë” ìì„¸íˆ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤. ê³¼ê±°ì— ë§ì”€í•˜ì‹  ê²ƒìœ¼ë¡œ ì•Œê³  ìˆëŠ”ë°, ê³ ìš©ëŸ‰ ê³ ê° ê¸°ë°˜ì— ì§‘ì¤‘í•´ì„œ ë³´ë©´ ë¯¸êµ­ì—ì„œ ì‹¤ì œë¡œ ëŒ€ë¶€ë¶„ì˜ ì‹œìˆ ì„ ìˆ˜í–‰í•˜ëŠ” ê³³ì´ ì•½ 2,000ê°œ ì •ë„ì— ë¶ˆê³¼í•˜ë‹¤ê³  í•˜ì…¨ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ 1,500ê°œë¥¼ ìƒê°í•´ë³´ë©´, ë¶„ëª…íˆ ì´ ëª¨ë“  ê³³ì´ ê³ ìš©ëŸ‰ ì™¸ê³¼ì˜ëŠ” ì•„ë‹ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ê·€ì‚¬ëŠ” í­ë„“ê²Œ í™•ì¥í•˜ë©´ì„œ ì •ë§ ë§ì€ ê±°ë˜ì²˜ì— ì§„ì…í•˜ëŠ” ë° ë§¤ìš° í›Œë¥­í•œ ì„±ê³¼ë¥¼ ê±°ë‘ì…¨ìŠµë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ 2026ë…„ ì„±ì¥ ì „ë§ì„ ìƒê°í•  ë•Œ, ê¸°ì¡´ ê±°ë˜ì²˜ ë‚´ì—ì„œ ë” ê¹Šì´ ì¹¨íˆ¬í•˜ëŠ” ê²ƒê³¼ ë” ë„“ê²Œ í™•ì¥í•˜ëŠ” ê²ƒì˜ ë¹„ì¤‘ì´ ê°ê° ì–´ëŠ ì •ë„ì…ë‹ˆê¹Œ? ì•„ë§ˆë„ ê·¸ ê³„ì •ë“¤ ì¤‘ ìƒë‹¹ìˆ˜ê°€ ê±°ë˜ëŸ‰ì´ ë§ì€ ê³„ì •ë“¤ì¼ ê²ƒìœ¼ë¡œ ìƒê°ë˜ëŠ”ë°, ì´ì œëŠ” ìƒëŒ€ì ìœ¼ë¡œ ê·œëª¨ê°€ ì‘ì€ ê³„ì •ë“¤ì„ ì¶”ê°€í•˜ê²Œ ë˜ëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. ê·¸ ë¶€ë¶„ì— ëŒ€í•´ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>CEO & Director: Yes. So in the U.S., I think, obviously, we're going to continue to expand the number of accounts. We add accounts every day. I think Jeff today had 2 additional -- 3 additional accounts. So that's also going to continue to be a part of that growth process for us. But it's also -- I think we're going to be going deeper in increasing the utilization rate as the surgeons work through their adoption curve, I think you're going to see a lot more acceleration from that standpoint in terms of enhancing the utilization in those accounts.</td><td>**CEO & Director:** ë„¤, ë¯¸êµ­ ì‹œì¥ì—ì„œëŠ” ë‹¹ì—°íˆ ê±°ë˜ì²˜ ìˆ˜ë¥¼ ê³„ì† í™•ëŒ€í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤. ë§¤ì¼ ìƒˆë¡œìš´ ê±°ë˜ì²˜ê°€ ì¶”ê°€ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ë§Œ í•´ë„ Jeffê°€ 2ê°œ, ì•„ë‹ˆ 3ê°œì˜ ê±°ë˜ì²˜ë¥¼ ì¶”ê°€í–ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ìš°ë¦¬ ì„±ì¥ ê³¼ì •ì˜ ì¼ë¶€ë¡œ ê³„ì†ë  ê²ƒì…ë‹ˆë‹¤. <br><br>í•˜ì§€ë§Œ ê·¸ê²ƒë§Œì´ ì•„ë‹™ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë” ê¹Šì´ ë“¤ì–´ê°€ì„œ í™œìš©ë¥ ì„ ë†’ì—¬ê°ˆ ê²ƒì…ë‹ˆë‹¤. ì™¸ê³¼ì˜ë“¤ì´ ë„ì… ê³¡ì„ ì„ ê±°ì¹˜ë©´ì„œ ìµìˆ™í•´ì§€ë©´, í•´ë‹¹ ê±°ë˜ì²˜ë“¤ì˜ í™œìš©ë„ë¥¼ ë†’ì´ëŠ” ì¸¡ë©´ì—ì„œ í›¨ì”¬ ë” í° ê°€ì†í™”ë¥¼ ë³´ê²Œ ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>K. Gong: JPMorgan Chase & Co, Research Division And then I guess I do want to touch on the competitive landscape, right? You had Sientra, like they haven't exactly exited the market, but they've definitely maybe been deemphasizing that piece of their business. You have the large players, J&J and Alcon, but arguably, breast augmentation also isn't a big focus for them. But clearly, you've come into the market and really taken it by storm, getting to 20% share within essentially a year is a very big success. So are you seeing anything on the competitive front? Any kind of reaction?</td><td>**K. Gong:** ê·¸ë¦¬ê³  ê²½ìŸ í™˜ê²½ì— ëŒ€í•´ì„œë„ ë§ì”€ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. Sientraì˜ ê²½ìš° ì‹œì¥ì—ì„œ ì™„ì „íˆ ì² ìˆ˜í•œ ê²ƒì€ ì•„ë‹ˆì§€ë§Œ, í™•ì‹¤íˆ ê·¸ ì‚¬ì—… ë¶€ë¬¸ì— ëŒ€í•œ ë¹„ì¤‘ì„ ì¤„ì´ê³  ìˆëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. J&Jë‚˜ Alcon ê°™ì€ ëŒ€í˜• ì—…ì²´ë“¤ë„ ìˆì§€ë§Œ, ì†”ì§íˆ ë§í•´ì„œ ìœ ë°©í™•ëŒ€ìˆ ì´ ê·¸ë“¤ì—ê²Œ í° ì§‘ì¤‘ ë¶„ì•¼ëŠ” ì•„ë‹™ë‹ˆë‹¤. í•˜ì§€ë§Œ ê·€ì‚¬ëŠ” ì‹œì¥ì— ì§„ì…í•´ì„œ ì •ë§ ëŒí’ì„ ì¼ìœ¼ì¼°ê³ , ì‚¬ì‹¤ìƒ 1ë…„ ë§Œì— 20% ì ìœ ìœ¨ì„ ë‹¬ì„±í•œ ê²ƒì€ ì—„ì²­ë‚œ ì„±ê³µì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ê²½ìŸì‚¬ë“¤ì˜ ì›€ì§ì„ì´ ë³´ì´ì‹œë‚˜ìš”? ì–´ë–¤ ë°˜ì‘ì´ ìˆìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>CEO & Director: No, I think you see a lot of one-offs. I wouldn't say there's a real concerted effort by either of those players. And I think while they're sizable businesses, when we look at it, within the portfolio of those companies, it's actually very small. And these are not categories that are very prioritized for the J&Js and the AbbVies of the world. So we haven't seen a significant competitive response. And quite frankly, I'm not sure that's surprising. These are not businesses that are priorities, and that's really enabled us to get significant traction in the U.S.</td><td>**CEO & Director:** ì•„ë‹ˆìš”, ì¼íšŒì„± ì›€ì§ì„ë“¤ì€ ë§ì´ ë³´ì´ì§€ë§Œ, ê·¸ ê²½ìŸì‚¬ë“¤ì´ ì‹¤ì œë¡œ ì¡°ì§ì ì¸ ë…¸ë ¥ì„ ê¸°ìš¸ì´ê³  ìˆë‹¤ê³ ëŠ” ë³´ì§€ ì•ŠìŠµë‹ˆë‹¤. ê·¸ë“¤ì´ ìƒë‹¹í•œ ê·œëª¨ì˜ ì‚¬ì—…ì„ í•˜ê³  ìˆëŠ” ê²ƒì€ ë§ì§€ë§Œ, ì €í¬ê°€ ë³´ê¸°ì— ê·¸ íšŒì‚¬ë“¤ì˜ í¬íŠ¸í´ë¦¬ì˜¤ ë‚´ì—ì„œëŠ” ì‚¬ì‹¤ ë§¤ìš° ì‘ì€ ë¶€ë¶„ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŸ° ì¹´í…Œê³ ë¦¬ë“¤ì€ J&Jë‚˜ AbbVie ê°™ì€ íšŒì‚¬ë“¤ì—ê²Œ ìš°ì„ ìˆœìœ„ê°€ ë†’ì€ ë¶„ì•¼ê°€ ì•„ë‹™ë‹ˆë‹¤. ê·¸ë˜ì„œ ì €í¬ëŠ” ì˜ë¯¸ ìˆëŠ” ê²½ìŸ ëŒ€ì‘ì„ ë³´ì§€ ëª»í–ˆìŠµë‹ˆë‹¤. ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´, ì´ê±´ ê·¸ë¦¬ ë†€ë¼ìš´ ì¼ë„ ì•„ë‹™ë‹ˆë‹¤. ì´ë“¤ì€ ìš°ì„ ìˆœìœ„ê°€ ì•„ë‹Œ ì‚¬ì—…ë“¤ì´ê³ , ê·¸ ë•ë¶„ì— ì €í¬ê°€ ë¯¸êµ­ ì‹œì¥ì—ì„œ ìƒë‹¹í•œ ê²¬ì¸ë ¥ì„ í™•ë³´í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>K. Gong: JPMorgan Chase & Co, Research Division Then on the reconstruction side, you just submitted that in the U.S. in December. Your presentation has more of a 2027 benefit, but as it has the opportunity to potentially double your addressable opportunity in the U.S., definitely worth talking about. When we think about why the U.S. is a better market for that, you have better reimbursement in place. So when we think about the competitive positioning there, clearly, you're having success on the augmentation side. But is that same kind of -- I don't want to maybe call it hands off, but a little bit of a looser approach from your competitors, the same thing we can expect in reconstruction once you start launching there?</td><td>**K. Gong:** ì¬ê±´ ì‹œìˆ  ì¸¡ë©´ì—ì„œ ë³´ë©´, 12ì›”ì— ë¯¸êµ­ì—ì„œ ì œì¶œí•˜ì…¨ì£ . ë°œí‘œ ìë£Œì—ëŠ” 2027ë…„ íš¨ìµì´ ë” ë§ì´ ë‚˜ì™€ ìˆì§€ë§Œ, ë¯¸êµ­ì—ì„œ ì ì¬ì ìœ¼ë¡œ ì‹œì¥ ê¸°íšŒë¥¼ ë‘ ë°°ë¡œ ëŠ˜ë¦´ ìˆ˜ ìˆë‹¤ëŠ” ì ì—ì„œ í™•ì‹¤íˆ ë…¼ì˜í•  ê°€ì¹˜ê°€ ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ì´ ë” ë‚˜ì€ ì‹œì¥ì¸ ì´ìœ ë¥¼ ìƒê°í•´ë³´ë©´, ë³´í—˜ ê¸‰ì—¬ ì²´ê³„ê°€ ë” ì˜ ê°–ì¶°ì ¸ ìˆìŠµë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ê²½ìŸ í¬ì§€ì…”ë‹ ì¸¡ë©´ì—ì„œ, ì¦ëŒ€ ì‹œìˆ  ìª½ì—ì„œëŠ” ë¶„ëª…íˆ ì„±ê³µì„ ê±°ë‘ê³  ê³„ì‹ ë°ìš”. ê²½ìŸì‚¬ë“¤ì˜ ê·¸ëŸ° ì ‘ê·¼ ë°©ì‹ - ë°©ê´€ì ì´ë¼ê³  í• ê¹Œìš”, ì•„ë‹ˆë©´ ì¢€ ë” ëŠìŠ¨í•œ ì ‘ê·¼ì´ë¼ê³  í•´ì•¼ í• ê¹Œìš” - ì¬ê±´ ì‹œìˆ  ì¶œì‹œë¥¼ ì‹œì‘í•˜ë©´ ê·¸ìª½ì—ì„œë„ ë˜‘ê°™ì´ ê¸°ëŒ€í•  ìˆ˜ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>CEO & Director: Yes. I think, first off, once we get the indication approval, I think we are going to get the same type of traction in the Recon indication that we've gotten in the augmentation. I think we -- by having that superior product, we already have establishment and with our Flora tissue expander in those accounts. So I would expect that, that acceleration actually be somewhat quicker than what we've seen from the augmentation where we're really starting at 0. So I think in terms of the competitive response, I don't think it's going to be any different, Allen. In those -- in the Recon indication, as I mentioned before, the fundamental issue is these are not categories that they prioritize.</td><td>**CEO & Director:** ë„¤, ë¨¼ì € ì ì‘ì¦ ìŠ¹ì¸ì„ ë°›ê²Œ ë˜ë©´, ì¬ê±´(Recon) ì ì‘ì¦ì—ì„œë„ í™•ëŒ€(augmentation) ì ì‘ì¦ì—ì„œ ì–»ì—ˆë˜ ê²ƒê³¼ ë™ì¼í•œ ìˆ˜ì¤€ì˜ ê²¬ì¸ë ¥ì„ í™•ë³´í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ìš°ìˆ˜í•œ ì œí’ˆì„ ë³´ìœ í•˜ê³  ìˆê³ , ì´ë¯¸ Flora ì¡°ì§ í™•ì¥ê¸°ë¥¼ í†µí•´ í•´ë‹¹ ê±°ë˜ì²˜ë“¤ê³¼ì˜ ê´€ê³„ê°€ êµ¬ì¶•ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì‹¤ì§ˆì ìœ¼ë¡œ ì œë¡œì—ì„œ ì‹œì‘í–ˆë˜ í™•ëŒ€ ì ì‘ì¦ë³´ë‹¤ ê°€ì†í™”ê°€ ë‹¤ì†Œ ë¹ ë¥¼ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ê²½ìŸì‚¬ ëŒ€ì‘ ì¸¡ë©´ì—ì„œëŠ”, Allen, í¬ê²Œ ë‹¤ë¥´ì§€ ì•Šì„ ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. ì¬ê±´ ì ì‘ì¦ì˜ ê²½ìš°, ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ê·¼ë³¸ì ì¸ ë¬¸ì œëŠ” ê²½ìŸì‚¬ë“¤ì´ ì´ ì¹´í…Œê³ ë¦¬ë¥¼ ìš°ì„ ìˆœìœ„ì— ë‘ì§€ ì•ŠëŠ”ë‹¤ëŠ” ì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>K. Gong: JPMorgan Chase & Co, Research Division I guess touching on more product specific. PreservÃ© launching into the U.S. now. You've been doing -- you've been having more of an early experience internationally. It sounds like that early experience has been going well. The feedback has been good. And I just want to kind of compare and contrast that with Mia, right? In the presentation, you framed Mia as being definitely more of a premium product, but PreservÃ© is also, especially compared to your Ergonomix1, it is also a premium product. So when I think about having your entire -- the breadth of your portfolio now with PreservÃ© and Mia at the top, how are those kind of like working together in the portfolio?</td><td>**K. Gong:** ì´ì œ ì œí’ˆë³„ë¡œ ì¢€ ë” êµ¬ì²´ì ìœ¼ë¡œ ì—¬ì­¤ë³´ê² ìŠµë‹ˆë‹¤. PreservÃ©ê°€ ë¯¸êµ­ ì‹œì¥ì— ì¶œì‹œë˜ëŠ”ë°ìš”, í•´ì™¸ì—ì„œ ë¨¼ì € ê²½í—˜ì„ ìŒ“ì•„ì˜¤ì…¨ê³ , ì´ˆê¸° ë°˜ì‘ì´ ì¢‹ì•˜ë˜ ê²ƒìœ¼ë¡œ ë“¤ë¦½ë‹ˆë‹¤. í”¼ë“œë°±ë„ ê¸ì •ì ì´ì—ˆê³ ìš”. ì´ê±¸ Miaì™€ ë¹„êµí•´ë³´ê³  ì‹¶ì€ë°ìš”, ë°œí‘œ ìë£Œì—ì„œ Miaë¥¼ í™•ì‹¤íˆ ë” í”„ë¦¬ë¯¸ì—„ ì œí’ˆìœ¼ë¡œ í¬ì§€ì…”ë‹í•˜ì…¨ëŠ”ë°, PreservÃ©ë„ íŠ¹íˆ Ergonomix1ê³¼ ë¹„êµí•˜ë©´ í”„ë¦¬ë¯¸ì—„ ì œí’ˆì´ì–ì•„ìš”. ê·¸ë˜ì„œ ì´ì œ í¬íŠ¸í´ë¦¬ì˜¤ ì „ì²´ë¥¼ ë³´ë©´ PreservÃ©ì™€ Miaê°€ ìµœìƒìœ„ì— ìˆëŠ” êµ¬ì¡°ì¸ë°, ì´ ë‘ ì œí’ˆì´ í¬íŠ¸í´ë¦¬ì˜¤ ë‚´ì—ì„œ ì–´ë–»ê²Œ í•¨ê»˜ ì‘ë™í•˜ëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Yes. So I mean, the first thing, when you look at the U.S. right now, it's just going to be PreservÃ©. We are going to be submitting the PMA supplement really the beginning of this year. So I think in order to launch Mia, you need to have the ERGO 2, the ERGO 2 diamond. So I think that's more in the outer years. But outside the U.S., I think they've worked very complementary. With Mia, it's a more premium segment. There are some limitations in terms of the cup size and the type of surgeons that are willing to use it. So in a lot of cases, with the transactionary approach and the fact that the MA does not have any scar on the breast is a significant benefit, but it's much more in the premium segment. And what we've seen outside the U.S. is actually the Mia accounts are also adopting PreservÃ©, and you're seeing hand-in-hand significant growth for both businesses. So it hasn't really cannibalized the business in the early stages. So we're very pleased with that. But they work very well together, especially when you have that segmentation and there are specific benefits for MA that you will not get from PreservÃ©.</td><td>**CEO & Director:** ë„¤. ë¨¼ì € í˜„ì¬ ë¯¸êµ­ ì‹œì¥ì„ ë³´ë©´ PreservÃ©ë§Œ ì¶œì‹œë  ì˜ˆì •ì…ë‹ˆë‹¤. PMA ë³´ì™„ ìë£Œë¥¼ ì˜¬í•´ ì´ˆì— ì œì¶œí•  ê³„íšì´ê³ ìš”. Miaë¥¼ ì¶œì‹œí•˜ë ¤ë©´ ERGO 2ì™€ ERGO 2 ë‹¤ì´ì•„ëª¬ë“œê°€ í•„ìš”í•˜ê¸° ë•Œë¬¸ì— ì´ëŠ” ì¢€ ë” ë¨¼ ë¯¸ë˜ì˜ ì¼ì´ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œëŠ” ë‘ ì œí’ˆì´ ë§¤ìš° ìƒí˜¸ë³´ì™„ì ìœ¼ë¡œ ì‘ìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. MiaëŠ” ì¢€ ë” í”„ë¦¬ë¯¸ì—„ ì„¸ê·¸ë¨¼íŠ¸ì— í•´ë‹¹í•©ë‹ˆë‹¤. ì»µ ì‚¬ì´ì¦ˆ ì¸¡ë©´ì—ì„œ ì¼ë¶€ ì œì•½ì´ ìˆê³ , ì´ë¥¼ ì‚¬ìš©í•˜ë ¤ëŠ” ì™¸ê³¼ì˜ë“¤ë„ ì œí•œì ì…ë‹ˆë‹¤. ë§ì€ ê²½ìš°ì— ê²½ì•¡ì™€ ì ‘ê·¼ë²•(transaxillary approach)ê³¼ MAê°€ ìœ ë°©ì— í‰í„°ë¥¼ ì „í˜€ ë‚¨ê¸°ì§€ ì•ŠëŠ”ë‹¤ëŠ” ì ì´ ìƒë‹¹í•œ ì¥ì ì´ì§€ë§Œ, í›¨ì”¬ ë” í”„ë¦¬ë¯¸ì—„ ì„¸ê·¸ë¨¼íŠ¸ì— ì†í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œ ì €í¬ê°€ í™•ì¸í•œ ë°”ë¡œëŠ” ì‹¤ì œë¡œ Mia ê³„ì •ë“¤ë„ PreservÃ©ë¥¼ í•¨ê»˜ ë„ì…í•˜ê³  ìˆê³ , ë‘ ì‚¬ì—… ëª¨ë‘ì—ì„œ ìƒë‹¹í•œ ì„±ì¥ì„ ë™ì‹œì— ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ˆê¸° ë‹¨ê³„ì—ì„œ ì‚¬ì—… ì ì‹ í˜„ìƒì€ ì‹¤ì œë¡œ ë°œìƒí•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ì´ ì ì— ëŒ€í•´ ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‘ ì œí’ˆì€ íŠ¹íˆ ì„¸ë¶„í™”ëœ ì‹œì¥ì—ì„œ ë§¤ìš° ì˜ ì‘ë™í•˜ê³  ìˆìœ¼ë©°, MAì—ì„œë§Œ ì–»ì„ ìˆ˜ ìˆëŠ” íŠ¹ì • í˜œíƒë“¤ì´ PreservÃ©ì™€ëŠ” êµ¬ë¶„ë˜ê¸° ë•Œë¬¸ì— ìƒí˜¸ ë³´ì™„ì ìœ¼ë¡œ ì˜ ê¸°ëŠ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>K. Gong: JPMorgan Chase & Co, Research Division And then I guess, diving a little bit deeper into international markets. Latin America, I think it's been struggling for a while now. We started to see stabilization this year, but not exactly a recovery. So did that continue into fourth quarter of stabilization, but maybe not really recovery? And then what's the right expectation for 2026?</td><td>**K. Gong:** ê·¸ë¦¬ê³  í•´ì™¸ ì‹œì¥ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì‚´í´ë³´ë©´, ë¼í‹´ì•„ë©”ë¦¬ì¹´ëŠ” ê½¤ ì˜¤ë«ë™ì•ˆ ì–´ë ¤ì›€ì„ ê²ªì–´ì™”ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì˜¬í•´ ë“¤ì–´ ì•ˆì •í™” ì¡°ì§ì´ ë³´ì´ê¸° ì‹œì‘í–ˆì§€ë§Œ, íšŒë³µì´ë¼ê³  ë³´ê¸°ëŠ” ì–´ë ¤ìš´ ìƒí™©ì¸ë°ìš”. 4ë¶„ê¸°ì—ë„ ì´ëŸ¬í•œ ì•ˆì •í™” ì¶”ì„¸ëŠ” ì´ì–´ì¡Œì§€ë§Œ ì‹¤ì§ˆì ì¸ íšŒë³µì€ ì•„ì§ ë‚˜íƒ€ë‚˜ì§€ ì•Šì€ ê±´ê°€ìš”? ê·¸ë¦¬ê³  2026ë…„ì— ëŒ€í•œ ì ì ˆí•œ ê¸°ëŒ€ì¹˜ëŠ” ì–´ëŠ ì •ë„ì¸ê°€ìš”?</td></tr>
<tr><td>Chief Financial Officer: Yes. I think without breaking out the fourth quarter, we haven't provided that detail yet, we'll do so on our fourth quarter call. But as you noted, we have seen a generally good performance out of Latin America with the exception of Brazil, which has been a little challenging for us. But as I noted, it's been stable now for a couple of quarters, really the back half of last year. It's really stabilized. And as we move into 2026, we do have some programs to hopefully accelerate growth there. PreservÃ© has launched in Brazil. We're seeing good demand for the product in that market. And so we do have expectations that we'll see some growth out of Brazil. Latin America as a whole, outside of that market has generally been pretty good for us. Mexico, Colombia, these are some of our biggest markets and there the demand remains very good. So I think overall, Latin America, we have good expectations for '26.</td><td>**Chief Financial Officer:** ë„¤, 4ë¶„ê¸° ì‹¤ì ì„ ë³„ë„ë¡œ ê³µê°œí•˜ì§€ëŠ” ì•Šì•˜ê³ , 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ë•Œ ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë§ì”€í•˜ì‹  ëŒ€ë¡œ, ë¸Œë¼ì§ˆì„ ì œì™¸í•œ ë¼í‹´ì•„ë©”ë¦¬ì¹´ ì§€ì—­ì—ì„œëŠ” ì „ë°˜ì ìœ¼ë¡œ ì–‘í˜¸í•œ ì‹¤ì ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ë¸Œë¼ì§ˆì€ ì €í¬ì—ê²Œ ë‹¤ì†Œ ì–´ë ¤ìš´ ì‹œì¥ì´ì—ˆìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ì œê°€ ì–¸ê¸‰í–ˆë“¯ì´, ì§€ë‚œí•´ í•˜ë°˜ê¸°ë¶€í„° ë‘ ë¶„ê¸° ì—°ì† ì•ˆì •ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì •ë§ ì•ˆì •í™”ë˜ì—ˆìŠµë‹ˆë‹¤. <br><br>2026ë…„ìœ¼ë¡œ ë“¤ì–´ê°€ë©´ì„œ ë¸Œë¼ì§ˆì—ì„œ ì„±ì¥ì„ ê°€ì†í™”í•  ìˆ˜ ìˆëŠ” ëª‡ ê°€ì§€ í”„ë¡œê·¸ë¨ì„ ì¤€ë¹„í•˜ê³  ìˆìŠµë‹ˆë‹¤. PreservÃ© ì œí’ˆì´ ë¸Œë¼ì§ˆì— ì¶œì‹œë˜ì—ˆê³ , í•´ë‹¹ ì‹œì¥ì—ì„œ ì¢‹ì€ ìˆ˜ìš”ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë¸Œë¼ì§ˆì—ì„œë„ ì–´ëŠ ì •ë„ ì„±ì¥ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¸Œë¼ì§ˆì„ ì œì™¸í•œ ë¼í‹´ì•„ë©”ë¦¬ì¹´ ì „ì²´ì ìœ¼ë¡œëŠ” ì €í¬ì—ê²Œ ê½¤ ì¢‹ì€ ì‹¤ì ì„ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. <budget:token_budget>200000</budget:token_budget><br><br>ë©•ì‹œì½”, ì½œë¡¬ë¹„ì•„ëŠ” ì €í¬ì˜ ê°€ì¥ í° ì‹œì¥ ì¤‘ ì¼ë¶€ì´ë©°, ì´ë“¤ ì§€ì—­ì—ì„œ ìˆ˜ìš”ëŠ” ì—¬ì „íˆ ë§¤ìš° ì–‘í˜¸í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì „ë°˜ì ìœ¼ë¡œ ë¼í‹´ ì•„ë©”ë¦¬ì¹´ì— ëŒ€í•´ì„œëŠ” 26ë…„ì— ì¢‹ì€ ì „ë§ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>K. Gong: JPMorgan Chase & Co, Research Division And then on the APAC side, right, it's a little bit interesting there because Japan and South Korea are undoubtedly success stories for ESTA where you have maybe a majority share, correct me if I'm wrong, at least a very significant share in both of those markets, and you got there relatively quickly. So I guess starting there, and I do want to talk on China after, you've already reached a really healthy share position in those markets. So how do you continue to drive growth there? You have mix upgrades, I imagine, but how do you grow the market further?</td><td>**K. Gong:** ì•„ì‹œì•„íƒœí‰ì–‘ ì§€ì—­ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ìë©´, ì¼ë³¸ê³¼ í•œêµ­ì€ ì˜ì‹¬í•  ì—¬ì§€ ì—†ì´ ESTAì˜ ì„±ê³µ ì‚¬ë¡€ì…ë‹ˆë‹¤. ì œê°€ ì˜ëª» ì•Œê³  ìˆë‹¤ë©´ ì •ì •í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤ë§Œ, ë‘ ì‹œì¥ ëª¨ë‘ì—ì„œ ê³¼ë°˜ ì ìœ ìœ¨ì€ ì•„ë‹ˆë”ë¼ë„ ìµœì†Œí•œ ìƒë‹¹íˆ ë†’ì€ ì ìœ ìœ¨ì„ í™•ë³´í•˜ê³  ê³„ì‹œê³ , ë¹„êµì  ë¹ ë¥¸ ì‹œì¼ ë‚´ì— ê·¸ ìœ„ì¹˜ì— ë„ë‹¬í•˜ì…¨ìŠµë‹ˆë‹¤. ìš°ì„  ê·¸ ë¶€ë¶„ë¶€í„° ì—¬ì­™ê³  ì‹¶ê³ ìš”, ì¤‘êµ­ì— ëŒ€í•´ì„œë„ ì´í›„ì— ë§ì”€ ë‚˜ëˆ„ê³  ì‹¶ìŠµë‹ˆë‹¤. ì´ë¯¸ í•´ë‹¹ ì‹œì¥ë“¤ì—ì„œ ë§¤ìš° ê±´ê°•í•œ ì ìœ ìœ¨ ìœ„ì¹˜ì— ë„ë‹¬í•˜ì…¨ëŠ”ë°, ê·¸ë ‡ë‹¤ë©´ ê·¸ê³³ì—ì„œ ì–´ë–»ê²Œ ì§€ì†ì ìœ¼ë¡œ ì„±ì¥ì„ ê²¬ì¸í•˜ì‹¤ ê³„íšì´ì‹ ê°€ìš”? ì œí’ˆ ë¯¹ìŠ¤ ì—…ê·¸ë ˆì´ë“œë¥¼ ìƒê°í•˜ê³  ê³„ì‹¤ ê²ƒ ê°™ì€ë°, ì‹œì¥ ìì²´ë¥¼ ì–´ë–»ê²Œ ë” ì„±ì¥ì‹œí‚¤ì‹¤ ê±´ê°€ìš”?</td></tr>
<tr><td>CEO & Director: Yes. I think in 2026, the back half of 2026 as well as into 2027, we're going to be launching PreservÃ© in those markets. That has, as I mentioned before, an opportunity not only to drive incremental share, but as you made the point, we already have sizable share. There is the opportunity to expand the market. So that's going to be a key driver in those markets and continue to drive that innovation. There's still opportunities for us to grow through our distributors. And I think we're very fortunate in the success we've had in those markets. But I think when you overlay that type of innovation with PreservÃ©, it has the opportunity to steal additional share, but also expand the category.</td><td>**CEO & Director:** ë„¤, 2026ë…„ í•˜ë°˜ê¸°ì™€ 2027ë…„ì— ê±¸ì³ í•´ë‹¹ ì‹œì¥ë“¤ì—ì„œ PreservÃ©ë¥¼ ì¶œì‹œí•  ì˜ˆì •ì…ë‹ˆë‹¤. ë§ì”€ë“œë ¸ë“¯ì´ ì´ ì œí’ˆì€ ì ìœ ìœ¨ì„ ì¶”ê°€ë¡œ í™•ë³´í•  ìˆ˜ ìˆëŠ” ê¸°íšŒì¼ ë¿ë§Œ ì•„ë‹ˆë¼, ì§€ì í•˜ì‹  ê²ƒì²˜ëŸ¼ ìš°ë¦¬ê°€ ì´ë¯¸ ìƒë‹¹í•œ ì ìœ ìœ¨ì„ ë³´ìœ í•˜ê³  ìˆê¸° ë•Œë¬¸ì— ì‹œì¥ ìì²´ë¥¼ í™•ëŒ€í•  ìˆ˜ ìˆëŠ” ê¸°íšŒì´ê¸°ë„ í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ê²ƒì´ í•´ë‹¹ ì‹œì¥ë“¤ì˜ í•µì‹¬ ì„±ì¥ ë™ë ¥ì´ ë  ê²ƒì´ë©° í˜ì‹ ì„ ì§€ì†ì ìœ¼ë¡œ ì´ëŒì–´ê°ˆ ê²ƒì…ë‹ˆë‹¤. ìœ í†µì—…ì²´ë“¤ì„ í†µí•œ ì„±ì¥ ê¸°íšŒë„ ì—¬ì „íˆ ì¡´ì¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ê°€ ì´ ì‹œì¥ë“¤ì—ì„œ ê±°ë‘” ì„±ê³µì€ ì •ë§ ë‹¤í–‰ìŠ¤ëŸ¬ìš´ ì¼ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ PreservÃ©ì™€ ê°™ì€ í˜ì‹ ì„ ë”í•˜ë©´ ì¶”ê°€ ì ìœ ìœ¨ì„ í™•ë³´í•  ìˆ˜ ìˆì„ ë¿ë§Œ ì•„ë‹ˆë¼ ì¹´í…Œê³ ë¦¬ ìì²´ë¥¼ í™•ì¥í•  ìˆ˜ ìˆëŠ” ê¸°íšŒê°€ ìƒê¹ë‹ˆë‹¤.</td></tr>
<tr><td>K. Gong: JPMorgan Chase & Co, Research Division On the other side, you have China, which in terms of pure market size, I think we were really bullish at the start. It was going to be the second largest market after the U.S. Unfortunately, the launch hasn't really had the traction that I think we really would have wanted in the bull case. You invested a bit more money into that business into your distributor specifically. So have you seen any of those efforts bearing fruit? And I guess just help us to understand why isn't the market doing quite as well, both maybe specifically for you and also just for breast augmentation as a whole?</td><td>**K. Gong:** ë°˜ëŒ€ë¡œ ì¤‘êµ­ì˜ ê²½ìš°ë¥¼ ë³´ë©´, ìˆœìˆ˜í•œ ì‹œì¥ ê·œëª¨ ì¸¡ë©´ì—ì„œ ì €í¬ëŠ” ì´ˆê¸°ì— ë¯¸êµ­ ë‹¤ìŒìœ¼ë¡œ ë‘ ë²ˆì§¸ë¡œ í° ì‹œì¥ì´ ë  ê²ƒì´ë¼ê³  ë§¤ìš° ë‚™ê´€ì ìœ¼ë¡œ ì „ë§í–ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì•ˆíƒ€ê¹ê²Œë„ ì œí’ˆ ì¶œì‹œê°€ ì €í¬ê°€ ê°•ì„¸ ì‹œë‚˜ë¦¬ì˜¤ì—ì„œ ê¸°ëŒ€í–ˆë˜ ë§Œí¼ì˜ ê²¬ì¸ë ¥ì„ ì–»ì§€ ëª»í–ˆìŠµë‹ˆë‹¤. ê·€ì‚¬ëŠ” íŠ¹íˆ ìœ í†µì—…ì²´ì— ì¶”ê°€ íˆ¬ìë¥¼ ì§„í–‰í•˜ì…¨ëŠ”ë°ìš”. ê·¸ëŸ¬í•œ ë…¸ë ¥ë“¤ì´ ê²°ì‹¤ì„ ë§ºê³  ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì™œ ì‹œì¥ì´ ì˜ˆìƒë§Œí¼ ì˜ ë˜ì§€ ì•ŠëŠ”ì§€, ê·€ì‚¬ì˜ íŠ¹ì • ìƒí™©ê³¼ ìœ ë°©í™•ëŒ€ìˆ  ì‹œì¥ ì „ë°˜ì— ëŒ€í•´ ëª¨ë‘ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>CEO & Director: Yes. I think -- I mean, there's -- certainly, I think it's pretty well known some of the macroeconomic issues in China that's really impacted our category. So I think that's kind of suppressed the market opportunity certainly in the short term. In terms of our distributor, I think we've communicated that we were not as happy with their commercial development. We've seen a lot of progress over the last couple of quarters in terms of the increase in sellout. And our engagement has really been around to optimize a lot of their strategy, pricing points and things like that. In terms of creating awareness, I would say that distributor has done a very good job in that market. It's really about them building out their capabilities. It's a large market. But we fully expect that China will have in a year or 2 to have the same type of share that we see in other markets throughout Asia.</td><td>**CEO & Director:** ë„¤, ë§ì”€ë“œë¦¬ìë©´ ì¤‘êµ­ì˜ ê±°ì‹œê²½ì œì  ì´ìŠˆë“¤ì´ ìš°ë¦¬ ì¹´í…Œê³ ë¦¬ì— ì‹¤ì§ˆì ì¸ ì˜í–¥ì„ ë¯¸ì¹˜ê³  ìˆë‹¤ëŠ” ê²ƒì€ ì˜ ì•Œë ¤ì§„ ì‚¬ì‹¤ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ë‹¨ê¸°ì ìœ¼ë¡œëŠ” ì‹œì¥ ê¸°íšŒê°€ ë‹¤ì†Œ ì–µì œë˜ì–´ ìˆëŠ” ìƒí™©ì…ë‹ˆë‹¤. <br><br>ìœ í†µì—…ì²´ì™€ ê´€ë ¨í•´ì„œëŠ”, ê·¸ë“¤ì˜ ìƒì—…ì  ê°œë°œ ì„±ê³¼ì— ëŒ€í•´ ì €í¬ê°€ ë§Œì¡±í•˜ì§€ ëª»í–ˆë‹¤ëŠ” ì ì„ ì´ë¯¸ ë§ì”€ë“œë¦° ë°” ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì§€ë‚œ ëª‡ ë¶„ê¸° ë™ì•ˆ íŒë§¤ ì‹¤ì (sellout) ì¦ê°€ ì¸¡ë©´ì—ì„œ ìƒë‹¹í•œ ì§„ì „ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê·¸ë“¤ì˜ ì „ëµ, ê°€ê²© í¬ì¸íŠ¸ ë“±ì„ ìµœì í™”í•˜ëŠ” ë° ì§‘ì¤‘ì ìœ¼ë¡œ í˜‘ë ¥í•´ì™”ìŠµë‹ˆë‹¤. <br><br>ì¸ì§€ë„ ì œê³  ì¸¡ë©´ì—ì„œ ë³´ë©´, í•´ë‹¹ ìœ í†µì—…ì²´ëŠ” ê·¸ ì‹œì¥ì—ì„œ ë§¤ìš° ì¢‹ì€ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆë‹¤ê³  í‰ê°€í•©ë‹ˆë‹¤. ì§€ê¸ˆ ì¤‘ìš”í•œ ê²ƒì€ ê·¸ë“¤ì´ ì—­ëŸ‰ì„ êµ¬ì¶•í•´ ë‚˜ê°€ëŠ” ê²ƒì…ë‹ˆë‹¤. ì¤‘êµ­ì€ í° ì‹œì¥ì´ë‹ˆê¹Œìš”. í•˜ì§€ë§Œ ì¤‘êµ­ë„ 1~2ë…„ ë‚´ì— ì•„ì‹œì•„ì˜ ë‹¤ë¥¸ ì‹œì¥ë“¤ì—ì„œ ë³´ì´ëŠ” ê²ƒê³¼ ë™ì¼í•œ ìˆ˜ì¤€ì˜ ì ìœ ìœ¨ì„ í™•ë³´í•  ê²ƒìœ¼ë¡œ ì¶©ë¶„íˆ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>K. Gong: JPMorgan Chase & Co, Research Division Okay. That would be really great. So I guess like when I think about the 25% plus, that assumes in 2026, 2027, that assumes that China picks up?</td><td>**K. Gong:** <response><br><br>ë„¤, 25% ì´ìƒ ì„±ì¥ë¥ ì€ 2026ë…„ê³¼ 2027ë…„ì— ì¤‘êµ­ ì‹œì¥ì´ íšŒë³µëœë‹¤ëŠ” ê°€ì •ì„ í¬í•¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ìŠµë‹ˆë‹¤. ì¤‘êµ­ ì‹œì¥ì˜ íšŒë³µì„ ì „ì œë¡œ í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>CEO & Director: Yes. So we have -- the expectation is this year, we'll have some sales in China. And then as the market progresses and our distributor progresses, we expect that to grow in 2027 and beyond.</td><td>**CEO & Director:** ë„¤, ì˜¬í•´ ì¤‘êµ­ì—ì„œ ì¼ë¶€ ë§¤ì¶œì´ ë°œìƒí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‹œì¥ì´ ë°œì „í•˜ê³  ì €í¬ ìœ í†µì—…ì²´ê°€ ì„±ì¥í•¨ì— ë”°ë¼ 2027ë…„ ì´í›„ì—ëŠ” ë”ìš± í™•ëŒ€ë  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>K. Gong: JPMorgan Chase & Co, Research Division Got it. And then shifting over to the financials with the time we have left. I think one of the big benefits, again, of having the U.S. launch performing really well is that it is a higher-margin opportunity for you. You were able to get adjusted EBITDA profitability a little bit sooner than I think you were expecting. You're still on track for free cash flow positive next year. So how do you balance investing, adding another 15 sales reps in the U.S., maybe putting a little bit more effort into China as well to really get that jump started against continuing to drive leverage and maintaining cash flow discipline.</td><td>**K. Gong:** ì•Œê² ìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ë‚¨ì€ ì‹œê°„ ë™ì•ˆ ì¬ë¬´ ë¶€ë¶„ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ë¯¸êµ­ ì¶œì‹œê°€ ì •ë§ ì˜ ë˜ê³  ìˆëŠ” ê²ƒì˜ í° ì¥ì  ì¤‘ í•˜ë‚˜ëŠ” ë” ë†’ì€ ë§ˆì§„ ê¸°íšŒë¼ëŠ” ì ì…ë‹ˆë‹¤. ì˜ˆìƒë³´ë‹¤ ì¡°ê¸ˆ ë” ë¹¨ë¦¬ ì¡°ì • EBITDA ìˆ˜ìµì„±ì„ ë‹¬ì„±í•˜ì…¨ê³ ìš”. ë‚´ë…„ ì‰ì—¬í˜„ê¸ˆíë¦„(free cash flow) í”ŒëŸ¬ìŠ¤ ì „í™˜ë„ ì—¬ì „íˆ ê³„íšëŒ€ë¡œ ì§„í–‰ ì¤‘ì´ì‹œê³ ìš”. ê·¸ë ‡ë‹¤ë©´ ë¯¸êµ­ì— ì˜ì—… ì¸ë ¥ 15ëª…ì„ ì¶”ê°€ë¡œ íˆ¬ì…í•˜ê³ , ì¤‘êµ­ ì‹œì¥ë„ ë³¸ê²©ì ìœ¼ë¡œ ì‹œì‘í•˜ê¸° ìœ„í•´ ì¢€ ë” ë…¸ë ¥ì„ ê¸°ìš¸ì´ëŠ” ë“±ì˜ íˆ¬ìì™€, ë ˆë²„ë¦¬ì§€ë¥¼ ì§€ì†ì ìœ¼ë¡œ ë†’ì´ê³  í˜„ê¸ˆíë¦„ ê·œìœ¨ì„ ìœ ì§€í•˜ëŠ” ê²ƒ ì‚¬ì´ì—ì„œ ì–´ë–»ê²Œ ê· í˜•ì„ ë§ì¶”ì‹¤ ê³„íšì´ì‹ ê°€ìš”?</td></tr>
<tr><td>Chief Financial Officer: Yes. I think as Peter noted in the presentation, the infrastructure for our company has largely been built for the last 20 years, right? So you think about the various support structures you need, finance, legal, HR, all of those functions are in place. And the incremental spending for us from this point is really around commercial, right? So adding salespeople, adding support for those people, additional shipping costs, but these expenses will grow at a rate significantly lower than what the top line will for the next couple of years. And that's where this leverage really starts to flow through. We're talking about operating expenses, but you're also seeing it to a great degree on what's happening on the gross profitability line. We were in the mid-60s, 1.5 years, 2 years ago. Now we've pressed it above 70%. The U.S., recon, direct markets, all of these initiatives that are driving our growth are all at a higher gross profit margin than we have historically seen as our company. So you're seeing the gross profit increase dramatically, and then we're able to really control the amount of incremental spending we need to support the growth. And that leverage will start to become very apparent as you move through 2026 into 2027, and that's what ultimately drives us to this cash flow breakeven that we expect to achieve at some point this year.</td><td>**Chief Financial Officer:** ë„¤, í”¼í„°ê°€ ë°œí‘œì—ì„œ ì–¸ê¸‰í–ˆë“¯ì´, ìš°ë¦¬ íšŒì‚¬ì˜ ì¸í”„ë¼ëŠ” ì§€ë‚œ 20ë…„ê°„ ëŒ€ë¶€ë¶„ êµ¬ì¶•ì´ ì™„ë£Œëœ ìƒíƒœì…ë‹ˆë‹¤. ì¬ë¬´, ë²•ë¬´, HR ë“± í•„ìš”í•œ ê°ì¢… ì§€ì› ì¡°ì§ë“¤ì´ ì´ë¯¸ ê°–ì¶°ì ¸ ìˆì£ . ê·¸ë˜ì„œ ì•ìœ¼ë¡œ ìš°ë¦¬ì˜ ì¶”ê°€ ì§€ì¶œì€ ì‚¬ì‹¤ìƒ ì˜ì—… ë¶€ë¬¸ì— ì§‘ì¤‘ë©ë‹ˆë‹¤. ì˜ì—… ì¸ë ¥ ì¶©ì›, ê·¸ë“¤ì„ ìœ„í•œ ì§€ì›, ì¶”ê°€ ë°°ì†¡ë¹„ ì •ë„ì¸ë°, ì´ëŸ° ë¹„ìš©ë“¤ì€ í–¥í›„ ëª‡ ë…„ê°„ ë§¤ì¶œ ì¦ê°€ìœ¨ë³´ë‹¤ í›¨ì”¬ ë‚®ì€ ì†ë„ë¡œ ì¦ê°€í•  ê²ë‹ˆë‹¤. ë°”ë¡œ ì—¬ê¸°ì„œ ë ˆë²„ë¦¬ì§€ íš¨ê³¼ê°€ ë³¸ê²©ì ìœ¼ë¡œ ë‚˜íƒ€ë‚˜ê¸° ì‹œì‘í•˜ëŠ” ê±°ì£ . <br><br>ì§€ê¸ˆ ìš´ì˜ë¹„ìš© ì–˜ê¸°ë¥¼ í•˜ê³  ìˆì§€ë§Œ, ë§¤ì¶œì´ì´ìµë¥ (gross profitability)ì—ì„œë„ ì´ëŸ° íš¨ê³¼ê°€ í¬ê²Œ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. 1ë…„ ë°˜ì—ì„œ 2ë…„ ì „ë§Œ í•´ë„ ìš°ë¦¬ëŠ” 60% ì¤‘ë°˜ëŒ€ì˜€ê±°ë“ ìš”. í˜„ì¬ 70%ë¥¼ ë„˜ì–´ì„°ìŠµë‹ˆë‹¤. ë¯¸êµ­ ì‹œì¥, ë¦¬ì½˜(reconditioning), ì§ì ‘ íŒë§¤ ì‹œì¥ ë“± ìš°ë¦¬ì˜ ì„±ì¥ì„ ê²¬ì¸í•˜ëŠ” ëª¨ë“  ì´ë‹ˆì…”í‹°ë¸Œë“¤ì´ ì—­ì‚¬ì ìœ¼ë¡œ ìš°ë¦¬ íšŒì‚¬ê°€ ê²½í—˜í–ˆë˜ ê²ƒë³´ë‹¤ ë†’ì€ ë§¤ì¶œì´ì´ìµë¥ ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ë§¤ì¶œì´ì´ìµì´ ê·¹ì ìœ¼ë¡œ ì¦ê°€í•˜ëŠ” ê²ƒì„ ë³´ì‹¤ ìˆ˜ ìˆê³ , ë™ì‹œì— ì„±ì¥ì„ ë’·ë°›ì¹¨í•˜ëŠ” ë° í•„ìš”í•œ ì¶”ê°€ ì§€ì¶œì„ íš¨ê³¼ì ìœ¼ë¡œ í†µì œí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë ˆë²„ë¦¬ì§€ íš¨ê³¼ëŠ” 2026ë…„ì„ ê±°ì³ 2027ë…„ìœ¼ë¡œ ê°€ë©´ì„œ ë§¤ìš° ëª…í™•í•˜ê²Œ ë‚˜íƒ€ë‚  ê²ƒì´ë©°, ì´ê²ƒì´ ê¶ê·¹ì ìœ¼ë¡œ ì˜¬í•´ ì¤‘ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ëŠ” í˜„ê¸ˆíë¦„ ì†ìµë¶„ê¸°ì ìœ¼ë¡œ ìš°ë¦¬ë¥¼ ì´ë„ëŠ” ì›ë™ë ¥ì…ë‹ˆë‹¤.</td></tr>
<tr><td>K. Gong: JPMorgan Chase & Co, Research Division So as an extension to that, you clearly -- you're adding more reps in the U.S. just to support the augmentation launch, but then next year, you have reconstruction. The year after that or in 2027, you might be moving into glut as well. So when I think about the need to potentially expand your sales force to address those targets, do you think you can do that with like these additional 15 on top of the 40 or so you have today? Or will there be additional rep adds needed?</td><td>**K. Gong:** ê·¸ë˜ì„œ ê·¸ê²ƒì˜ ì—°ì¥ì„ ìƒì—ì„œ ì§ˆë¬¸ë“œë¦¬ìë©´, ë¶„ëª…íˆ ê·€ì‚¬ëŠ” ì¦ëŒ€ìˆ  ì¶œì‹œë¥¼ ì§€ì›í•˜ê¸° ìœ„í•´ ë¯¸êµ­ì—ì„œ ë” ë§ì€ ì˜ì—… ì¸ë ¥ì„ ì¶”ê°€í•˜ê³  ê³„ì‹ ë°, ë‚´ë…„ì—ëŠ” ì¬ê±´ìˆ ë„ ìˆê³ , ê·¸ ë‹¤ìŒ í•´ë‚˜ 2027ë…„ì—ëŠ” ë‘”ë¶€ ì‹œì¥ìœ¼ë¡œë„ ì§„ì¶œí•˜ì‹¤ ìˆ˜ ìˆì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ì´ëŸ¬í•œ ëª©í‘œ ì‹œì¥ë“¤ì„ ê³µëµí•˜ê¸° ìœ„í•´ ì ì¬ì ìœ¼ë¡œ ì˜ì—… ì¡°ì§ì„ í™•ëŒ€í•´ì•¼ í•  í•„ìš”ì„±ì„ ê³ ë ¤í•  ë•Œ, í˜„ì¬ ë³´ìœ í•˜ì‹  ì•½ 40ëª…ì— ì¶”ê°€ë¡œ 15ëª… ì •ë„ë©´ ì¶©ë¶„í•˜ë‹¤ê³  ë³´ì‹œë‚˜ìš”? ì•„ë‹ˆë©´ ì¶”ê°€ì ì¸ ì˜ì—… ì¸ë ¥ ì¦ì›ì´ ë” í•„ìš”í• ê¹Œìš”?</td></tr>
<tr><td>Chief Financial Officer: Yes. I think, again, it is -- we will continue to invest in commercial and primarily again to support the United States, as you described. But the incremental investment is around adding sales reps and the people needed to support them. So if we have 40-ish sales reps now, we'll add another 15 this year to support continued growth through '26. We'll see another incremental step-up in '27 to support recon. But if you think about the revenue potential that, that drives, given the size of the markets and the profitability of the markets in the United States, it's spending that -- it's going to -- the contribution margin from those sales over the next couple of years is going to be very significant.</td><td>**Chief Financial Officer:** ë„¤, ë§ì”€ë“œë¦¬ìë©´, ê³„ì†í•´ì„œ ìƒì—… ë¶€ë¬¸ì— íˆ¬ìí•  ê²ƒì´ë©° ì£¼ë¡œ ë§ì”€í•˜ì‹  ëŒ€ë¡œ ë¯¸êµ­ ì‹œì¥ì„ ì§€ì›í•˜ëŠ” ë° ì§‘ì¤‘í•  ê²ƒì…ë‹ˆë‹¤. ë‹¤ë§Œ ì¶”ê°€ íˆ¬ìëŠ” ì˜ì—… ì¸ë ¥ê³¼ ì´ë“¤ì„ ì§€ì›í•˜ëŠ” ì¸ë ¥ì„ í™•ì¶©í•˜ëŠ” ë° ì§‘ì¤‘ë©ë‹ˆë‹¤. í˜„ì¬ ì•½ 40ëª…ì˜ ì˜ì—… ë‹´ë‹¹ìê°€ ìˆëŠ”ë°, ì˜¬í•´ 15ëª…ì„ ì¶”ê°€ë¡œ ì±„ìš©í•´ì„œ 26ë…„ê¹Œì§€ ì§€ì†ì ì¸ ì„±ì¥ì„ ë’·ë°›ì¹¨í•  ê³„íšì…ë‹ˆë‹¤. 27ë…„ì—ëŠ” ì¬ê±´ìˆ (recon)ì„ ì§€ì›í•˜ê¸° ìœ„í•´ ë˜ í•œ ì°¨ë¡€ ì¦ì›ì´ ìˆì„ ê²ƒì…ë‹ˆë‹¤. <br><br>ë¯¸êµ­ ì‹œì¥ì˜ ê·œëª¨ì™€ ìˆ˜ìµì„±ì„ ê³ ë ¤í•˜ë©´, ì´ëŸ¬í•œ íˆ¬ìê°€ ì°½ì¶œí•˜ëŠ” ë§¤ì¶œ ì ì¬ë ¥ì„ ìƒê°í•´ë³´ì‹œë©´, í–¥í›„ ëª‡ ë…„ê°„ ì´ëŸ¬í•œ ì˜ì—… í™œë™ì—ì„œ ë‚˜ì˜¤ëŠ” ê³µí—Œì´ìµ(contribution margin)ì€ ë§¤ìš° ìƒë‹¹í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>K. Gong: JPMorgan Chase & Co, Research Division Got it. Unfortunately, that's all the time we have left. Thank you so much for the time today.</td><td>**K. Gong:** ì•Œê² ìŠµë‹ˆë‹¤. ì•„ì‰½ì§€ë§Œ ì˜ˆì •ëœ ì‹œê°„ì´ ë‹¤ ë˜ì—ˆë„¤ìš”. ì˜¤ëŠ˜ ì‹œê°„ ë‚´ì£¼ì…”ì„œ ëŒ€ë‹¨íˆ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: Great. Thank you.</td><td>**Chief Financial Officer:** ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Thank you.</td><td>**CEO & Director:** ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># ESTA ì‹¤ì  ì»¨í¼ëŸ°ìŠ¤ì½œ ìš”ì•½<br><br>**ì£¼ìš” ì¬ë¬´ ì„±ê³¼ ë° ê°€ì´ë˜ìŠ¤**<br>- 4Q ë§¤ì¶œ $64-65M ë‹¬ì„±, 2025ë…„ ì „ì²´ 27% ì„±ì¥ ê¸°ë¡. 2026-2027ë…„ ìµœì†Œ 25% ì´ìƒ ì„±ì¥ ê°€ì´ë˜ìŠ¤ ì œì‹œí•˜ë©°, ì‹ ì œí’ˆ ìŠ¹ì¸ì´ë‚˜ ë¯¸êµ­ ì¬ê±´ ë§¤ì¶œì€ ë¯¸í¬í•¨ëœ ë³´ìˆ˜ì  ì „ë§<br>- ì¡°ì • EBITDA í‘ì ì „í™˜ì„ ì˜ˆìƒë³´ë‹¤ ì¡°ê¸° ë‹¬ì„±í–ˆìœ¼ë©°, 2026ë…„ ì¤‘ í˜„ê¸ˆíë¦„ ì†ìµë¶„ê¸°ì  ë„ë‹¬ ì˜ˆìƒ. ë§¤ì¶œì´ì´ìµë¥ ì€ mid-60%ëŒ€ì—ì„œ 70% ì´ìƒìœ¼ë¡œ ê°œì„ <br><br>**ë¯¸êµ­ ì‹œì¥ ì„±ì¥ ë™ë ¥**<br>- ë¯¸êµ­ ì‹œì¥ì ìœ ìœ¨ 1ë…„ ë§Œì— 20% ë‹¬ì„±. PreservÃ© ì œí’ˆ 2026ë…„ 1ë¶„ê¸° ì¶œì‹œ ì˜ˆì •ìœ¼ë¡œ ì‹œì¥ í™•ëŒ€ ë° ì ìœ ìœ¨ ìƒìŠ¹ ê¸°ëŒ€. 1,500ê°œ ì´ìƒ ê±°ë˜ì²˜ í™•ë³´ ì™„ë£Œ<br>- ì¬ê±´(reconstruction) ì ì‘ì¦ 2025ë…„ 12ì›” ì œì¶œ, 2027ë…„ ìŠ¹ì¸ ì‹œ ë¯¸êµ­ TAM 2ë°° í™•ëŒ€ ê°€ëŠ¥. ê²½ìŸì‚¬(J&J, Alcon)ëŠ” í•´ë‹¹ ì¹´í…Œê³ ë¦¬ë¥¼ ìš°ì„ ìˆœìœ„ë¡œ ë‘ì§€ ì•Šì•„ ê²½ìŸ ì••ë ¥ ì œí•œì <br><br>**êµ­ì œ ì‹œì¥ í˜„í™©**<br>- ì§ì ‘ íŒë§¤ ì‹œì¥(ìœ ëŸ½, ì•„ë¥´í—¨í‹°ë‚˜ ë“±)ì´ ì„±ì¥ ê²¬ì¸. ë¸Œë¼ì§ˆì€ ì•ˆì •í™” ë‹¨ê³„ì´ë©° PreservÃ© ì¶œì‹œë¡œ 2026ë…„ íšŒë³µ ê¸°ëŒ€<br>- ì¼ë³¸Â·í•œêµ­ì—ì„œ</p>
    <hr style="margin:50px 0;">
    
</body></html>